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A B S T R A C T
Background
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are the most frequent causes of bacterial sexually transmitted infections
(STIs). Management strategies that reduce losses in the clinical pathway from infection to cure might improve STI control and reduce
complications resulting from lack of, or inadequate, treatment.
Objectives
To assess the effectiveness and safety of home-based specimen collection as part of the management strategy for Chlamydia trachomatis
and Neisseria gonorrhoeae infections compared with clinic-based specimen collection in sexually-active people.
Search methods
We searched the Cochrane Sexually Transmitted Infections Group Specialized Register, the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE and LILACS on 27May 2015, together with theWorld Health Organization International
Clinical Trials Registry (ICTRP) and ClinicalTrials.gov. We also handsearched conference proceedings, contacted trial authors and
reviewed the reference lists of retrieved studies.
Selection criteria
Randomized controlled trials (RCTs) of home-based compared with clinic-based specimen collection in the management of C. tra-
chomatis and N. gonorrhoeae infections.
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Data collection and analysis
Three review authors independently assessed trials for inclusion, extracted data and assessed risk of bias. We contacted study authors for
additional information. We resolved any disagreements through consensus.We used standardmethodological procedures recommended
by Cochrane. The primary outcome was index case management, defined as the number of participants tested, diagnosed and treated,
if test positive.
Main results
Ten trials involving 10,479 participants were included. There was inconclusive evidence of an effect on the proportion of participants
with index case management (defined as individuals tested, diagnosed and treated for CT or NG, or both) in the group with home-
based (45/778, 5.8%) compared with clinic-based (51/788, 6.5%) specimen collection (risk ratio (RR) 0.88, 95% confidence interval
(CI) 0.60 to 1.29; 3 trials, I² = 0%, 1566 participants, moderate quality). Harms of home-based specimen collection were not evaluated
in any trial. All 10 trials compared the proportions of individuals tested. The results for the proportion of participants completing
testing had high heterogeneity (I² = 100%) and were not pooled. We could not combine data from individual studies looking at the
number of participants tested because the proportions varied widely across the studies, ranging from 30% to 96% in home group and
6% to 97% in clinic group (low-quality evidence). The number of participants with positive test was lower in the home-based specimen
collection group (240/2074, 11.6%) compared with the clinic-based group (179/967, 18.5%) (RR 0.72, 95% CI 0.61 to 0.86; 9 trials,
I² = 0%, 3041 participants, moderate quality).
Authors’ conclusions
Home-based specimen collection could result in similar levels of index case management for CT or NG infection when compared with
clinic-based specimen collection. Increases in the proportion of individuals tested as a result of home-based, compared with clinic-based,
specimen collection are offset by a lower proportion of positive results. The harms of home-based specimen collection compared with
clinic-based specimen collection have not been evaluated. Future RCTs to assess the effectiveness of home-based specimen collection
should be designed to measure biological outcomes of STI case management, such as proportion of participants with negative tests for
the relevant STI at follow-up.
P L A I N L A N G U A G E S U M M A R Y
Home-based specimen collection in the management of chlamydia and gonorrhoea infections
Review question: Cochrane authors reviewed evidence about the effects of self-collected specimens at home compared with specimens
collected at clinic on the clinical management of chlamydia and gonorrhoea infections.
Background: Chlamydia and gonorrhoea are common sexually transmitted infections (STI). Management of these infections might
be easier to achieve if people can collect specimens at home and send or take them to a laboratory, rather than having to go to a clinic.
Search date: This evidence is up to May 2015.
Study characteristics: We searched the available literature for trials in which people were invited either to collect specimens at home
or to attend a clinic for collection of specimens. We found 10 relevant trials in total. Three trials (including 1566 people) provided data
to assess the proportion of people who completed testing, diagnosis and treatment. All trials gave information about the percentages of
people who took self-collected specimens for detection of chlamydia and gonorrhoea infections at home and those who took the test
at a clinic. Nine studies reported percentages related to positive test results.
Funding sources: Trials in this review were funded by governmental or non-governmental organisations.
Key results: There was no evidence of a difference between home-based and clinic-based specimen collection in the proportion of
people who completed testing, diagnosis and treatment. In the home-based group 45 infections were detected and treated in a total
of 778 people invited to collect specimens at home. In the clinic-based group 51 infections were detected and treated in a total of
788 people invited to attend a clinic. We could not combine data from individual studies looking at the number of participants tested
because the proportions varied widely. A lower number of participants diagnosed in the home-based compared with the clinic-based
group was documented. The potential harms of testing with home-collected specimens were not evaluated in any trial.
Quality of the evidence: The GRADE quality for the main outcomes was moderate (index case management, positive test prevalence)
or low (proportion of individuals tested). The quality of evidence was downgraded because of methodological limitations in the studies.
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Conclusions: Home-based specimen collection could result in similar levels of index case management for Chlamydia trachomatis or
Neisseria gonorrhoeae infection when compared with clinic-based specimen collection. The safety of home-based specimen collection
compared with clinic-based specimen collection have not been evaluated.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Home-based compared with clinic-based specimen collection for Chlamydia trachomatis and Neisseria gonorrhoeae
Patient or population: Sexually active people
Setting: Outpatient
Intervention: Home-based specimen collection
Comparison: Clinic-based specimen collection
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with clinic-based
specimen collection for
CT and NG
Risk with Home-based
Index case management
(6 to 12 weeks of follow-
up)
Study population RR 0.88
(0.60 to 1.29)
1566
(3 RCTs) MODERATE 1
65 per 1000 57 per 1000
(39 to 83)
Moderate
105 per 1000 93 per 1000
(63 to 136)
Proportion of individuals
tested
(12 days to 8 weeks of
follow-upa)
Eight of the ten trials found that home-based spec-
imen collection resulted in more participants being
tested than clinic-based specimen collection
Not pooledb 10479
(10 RCTs) LOW2
Positive test prevalence Study population RR 0.72
(0.61 to 0.86)
3041
(9 RCTs) MODERATE1
185 per 1000 133 per 1000
(113 to 159)
Moderate
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368 per 1000 265 per 1000
(225 to 317)
Adverse effects of testing
c
No estimable No estimable - - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
aOne study included follow-up until 2 years
bDue to substantial heterogeneity (I2=100%)
cNo trials reported adverse effects of testing
1Downgraded one level due to serious risk of bias (concerns about blinding and attrition rate >20% in two studies)
2Downgraded two levels due to very serious risk of bias (all the trials had a high or unclear risk of bias in at least one key domain i.e.
random sequence generation, allocation concealment and blinding)
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B A C K G R O U N D
Description of the condition
Sexually transmitted infections (STIs) are defined as “infections
that are spread primarily through person-to-person sexual contact”
(WHO2004). In 2008, theWorldHealthOrganization estimated
that there were 499 million new cases of syphilis, gonorrhoea,
chlamydia and trichomoniasis in sexually-active adults around the
world (WHO2012). Although these are curable STIs, they are still
a public health problem, especially in low-income countries where
complaints about ulcerative diseases, genital symptoms such as
vaginal or urethral secretions, and acute and chronic complications
and sequelae of STIs are some of the main problems for which
adults seek health care. This implies high costs, not only in terms of
productivity by the loss of work days, but also for acute treatment
and lengthy management of the complications of STIs (Mayaud
2004).
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are
the most frequent causes of bacterial STIs (Workowski 2010).
Repeated infections cause complications and sequelae manifested
as pelvic inflammatory disease (PID), ectopic pregnancy, chronic
pelvic pain, and infertility (Carey 2010). Annual costs of treat-
ment for CT and NG infection and their sequelae exceed USD
2.5 billion in the United States of America (USA), of which man-
agement of PID is the largest component. The direct cost of cases
of CT and NG in women is estimated at USD 315 and USD
343 respectively, and in men USD 26 and USD 68; for PID the
direct cost is USD 1925. Indirect costs, such as productivity losses
per PID case, are estimated at USD 649 (Mehta 2002; Blandford
2006; Chesson 2008)
CT and NG infection management requires measures at several
levels to achieve disease control and reduce complications result-
ing from lack of treatment or inadequate treatment. Strategies
aiming to control the transmission of CT and NG could break
the epidemiological chain of infection, which would in turn make
related complications easier to treat because they would be less
severe (Low 2006). The aim of early diagnosis of CT and NG
infections is to reduce the burden of STIs, as these infections are
often asymptomatic and affect both index patients and their part-
ners (Low 2006). At the individual level, strengthening the clini-
cal care of patients with curable STI focuses on case management.
Comprehensive case management requires correct diagnosis, ade-
quate antibiotic treatment, establishment of prevention measures,
and notification and treatment of sexual partners (UNAIDS 1999;
WHO 2004; WHO 2005).
Many countries recommend testing for CT and NG to achieve
early diagnosis and timely treatment of infected individuals. For
example, the Centers for Disease Control and Prevention and the
US Preventive Services Task Force have recommended annual CT
screening for all sexually-active women aged 25 years or younger
(including pregnant women) and for sexually-active women older
than 25 years with risk factors, as well as annual gonorrhoea screen-
ing for at-risk sexually-active women (USPSTF 2007; Meyers
2008). The effectiveness of strategies to increase testing uptake
in reducing the population prevalence of these infections has not
been established (Manhart 2005; Low 2006; Low 2007). There
are many challenges to implementing such population-level pro-
grams because substantial numbers of people are lost at each step
in the pathway between infection, treatment seeking, diagnosis,
treatment, cure, and avoidance of re-infection (UNAIDS 1999).
STI case management usually starts with the patient attending
clinical healthcare settings for diagnosis and treatment. There are
several challenges to providing effective care in the clinical setting.
Where laboratory testing is available, clinical samples are often
taken by a healthcare professional and sent to a laboratory; other-
wise the patient needs to go to another clinic/laboratory to have
samples taken. Thus the patient needs to make at least one extra
visit before they receive their results and treatment, if indicated.
Nucleic acid amplification tests (NAATs) are now themost widely-
used diagnostic tests for CT and NG in many countries. Their
sensitivity ranges from 90% to 100%, and specificity is about 99%
(Gaydos 2004; Masek 2009), but these tests are expensive. Con-
ventional testing in women requires a pelvic examination, specu-
lum use, and urethral, cervical or vaginal swabs. These procedures
can be uncomfortable and may constitute barriers to testing be-
cause ofwomen’s anxiety and fear (Hobbs 2008; Shih 2011). These
are reasons for which clinic-based case management might result
in loss to follow-up andmissed opportunities for treatment (Rager
2001). In most low-income countries, access to laboratory-based
testing is limited, and treatment is often restricted to those pre-
senting with recognized clinical syndromes. Syndromic manage-
ment allows same-day treatment but is known to miss infections,
particularly in women, and also lacks specificity (WHO 2004). As
an alternative, rapid tests, applied at the point of care, are being
developed and evaluated. At present, there is wide variability in
the accuracy of these tests (Núñez-Forero 2012). Other concerns
about clinic-based testing include lack of privacy, confidentiality,
a sense of discrimination, and prejudice, which are common in
people who seek care for sexual complaints (Graseck 2011; Shih
2011).
Description of the intervention
CT and NG case management strategies that are based on mak-
ing etiological rather than syndromic diagnoses include: specimen
collection, diagnosis, treatment with a specific antibiotic, manage-
ment of sexual partners, and follow-up.
Home-based specimen collection is an alternative to clinic-based
specimen collection. Case management that uses home-based
specimen collection might differ from clinic-based procedures in
several ways (Table 1). First, home-based specimen collection re-
duces the total number of clinic visits. Second, the type of spec-
imen might differ; home-collection requires non-invasive speci-
6Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae
infections (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
mens but clinic-based strategies can use either non-invasive spec-
imens or conventional swab sites. Specimen transport conditions
and processes for ensuring follow-up for treatment might also dif-
fer (Graseck 2011; Shih 2011). Non-invasive specimen types, in-
cluding first-catch urine from men and vaginal swabs for women
have high sensitivity and specificity with NAAT and results from
home-collected specimens are as good as those based on physi-
cian-collected specimens (Hobbs 2008; Masek 2009). Case man-
agement activities common to strategies based on both home-
collected and clinic-collected specimens are: laboratory process-
ing; informing the patient of the test result; providing treatment;
notification and treatment of sexual partner(s); and follow-up
(UNAIDS 1999).
Home-based specimen collection gives the responsibility for col-
lecting the sample to the individual, and overcomes the poten-
tial barrier of attending a clinical setting for initial assessment
(Graseck 2011; Shih 2011). Several large-scale studies have inves-
tigated home-collection of specimens, including studies in Den-
mark (Andersen 2002), the United Kingdom (Macleod 2005;
Scott 2007), Sweden (Novak 2006), and the Netherlands (Götz
2006; Van Bergen 2006). Home-based specimen collection is fea-
sible, practical and acceptable, and is often preferred by patients
who have experienced both home- and clinic-based specimen col-
lection (Graseck 2011; Shih 2011).
How the intervention might work
Home-based specimen collection as a part of case management
might improve the control of CT and NG infection and decrease
costs if it reduces losses in the clinical pathway from infection to
cure, and results in more infected people and their sexual partners
being treated for STIs. Higher uptake of early diagnosis and treat-
ment might decrease complications like PID, ectopic pregnancy
and infertility if it reduces the risk of ascending infection and does
not increase reinfection rates (Low 2006).
Strategies for home-collected sampling could have advantages over
clinic-based strategies as they do not require the initial clinic visit
or a clinical examination (Graseck 2011). Barriers to testing in
both women and men could be reduced by self-collection of sam-
ples comfortably at home or privately by the patient in the clinic.
Avoidance of anxiety and fear that might occur in clinical practice
could also increase adherence to home-based sampling. Qualita-
tive data suggest that individuals who have undergone home-col-
lected sampling prefer the simplicity, security, and privacy of self-
collected specimens (Chernesky 2005; Gaydos 2006).
Why it is important to do this review
Currently, there is no clear evidence about the effects on clinical
case management of strategies for taking samples at home for test-
ing for CT and NG compared with taking samples in the clini-
cal setting. A systematic review would identify the strategies that
have been evaluated, and their relative effectiveness and safety, and
would allow the exploration of factors such as time to diagnosis,
complete testing, and adequate treatment that might influence the
strategy’s effectiveness for CT and NG case management.
O B J E C T I V E S
To assess the effectiveness and safety of home-based specimen
collection as part of the management strategy for Chlamydia
trachomatis and Neisseria gonorrhoeae infections compared with
clinic-based specimen collection in sexually-active people.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) in this review;
we accepted randomization at the level of individuals or clus-
ters. We excluded cross-over trials and quasi-randomized designs.
Cross-over trials are not appropriate because the intervention has
a lasting effect that would compromise entry to subsequent pe-
riods of a trial. We included all relevant RCTs regardless of their
publication status or language.
Types of participants
We included sexually-active people, women andmenwho were re-
cruited in clinical settings, such as primary care centres and special-
ized clinics, or by means of population registers. We also included
high-risk people such as men who have sex with men (MSM),
commercial sex workers or patients diagnosed with another STI.
The participants could be symptomatic or asymptomatic. We in-
cluded patients with previous infection by Chlamydia trachomatis
(CT) or Neisseria gonorrhoeae (NG) or the partners of individuals
diagnosed with either CT or NG. There were no restrictions by
age or type of sexual intercourse.
Types of interventions
We compared home-based specimen collection as part of a clinical
management strategy for CT and NG with clinic-based specimen
collection. The home-collected sample is taken by the participant
and returned for laboratory testing. Clinic-based specimen collec-
tion could be done by clinical staff or by the participant at the
clinic. This is a complex intervention and differences in the inter-
ventions are listed in Table 1.
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Types of outcome measures
Primary outcomes
• Index case management: number tested (with home- or
clinic-collected sample), diagnosed and treated for CT or NG or
both with a specific antibiotic, as a proportion of all participants
(UNAIDS 1999).
• Harms of testing (psychological trauma, over-diagnosis,
over-treatment, using definitions described by the authors).
Secondary outcomes
The first set of secondary outcomes includes the individual com-
ponents of the intervention (testing, diagnosis and treatment):
• Proportion of individuals tested: number of individuals
who provide a specimen for CT or NG testing divided by the
number of participants;
• Positive test prevalence: number of infections identified
divided by the number of people tested;
• Proportion of infections treated: number of people treated
divided by number of positive tests.
The second set of secondary outcomes includes additional activi-
ties that are part of comprehensive STI case management, but are
not part of the primary outcome:
• Proportion of sexual partners receiving treatment: number
of sexual partners receiving treatment divided by the number of
sexual partners of the individuals treated;
• Infection cured: number of individuals treated who have
evidence of being free from infection at least 12 months after the
start of the intervention divided by the number of individuals
treated.
The third set of secondary outcomes are process and economic
outcomes in the pathway of STI case management:
• Barriers to testing (any reason for not completing the
testing procedure);
• Feasibility (collection of the specimen reported as easy,
convenient);
• Acceptability (collection of the specimen reported as
comfortable, secure);
• Costs.
Search methods for identification of studies
We developed a systematic and highly-sensitive search strategy to
identify as many relevant RCTs meeting the inclusion criteria as
possible, irrespective of their language, publication date and pub-
lication status (published, unpublished, in press, and in progress).
We used both electronic searching in bibliographic databases and
handsearching, as described in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011).
We downloaded and managed the results of all searches using
Endnote bibliographic software. We deleted duplicate records of
the same study.
Electronic searches
The Trials Search Coordinator of the Sexually Transmitted In-
fections Cochrane Review Group implemented a comprehensive
search strategy to capture as many relevant RCTs as possible in
electronic databases. For this purpose, we used a combination of
exploded controlled vocabulary (MeSH, EMTREE, DeCS) and
free-text terms (considering spelling variants, plurals, synonyms,
acronyms and abbreviations) for home-based versus clinic-based
strategy forChlamydia trachomatis andNeisseria gonorrhoeae detec-
tion,with field labels, truncation, proximity operators andBoolean
operators. The sensitivity of the search strategies was improved
by including keywords from relevant RCTs detected by earlier
searches. We present the search strategies in Appendix 1.
Specifically, we searched the following electronic databases.
• The Cochrane Central Register of Controlled Trials
(CENTRAL), Ovid platform (1991 to 27 May 2015).
• MEDLINE, Ovid platform (January 1946 to 27 May
2015).
• MEDLINE In-Process & Other Non-Indexed Citations,
Ovid platform (1946 to 27 May 2015).
• MEDLINE Daily Update, Ovid platform (1946 to 27 May
2015).
• EMBASE.com (1947 to 27 May 2015).
• LILACS, iAHx interface (1982 to 27 May 2015).
To search MEDLINE we used the Cochrane Highly Sensitive
Search Strategy for identifying RCTs: sensitivity and precision
maximizing version (2008 revision), Ovid format (Higgins 2011).
We combined the LILACS search strategy with the RCT filter for
the iAHx interface.
These searches have been updated within 6 months before publi-
cation of the review.
Searching other resources
We attempted to identify additional relevant RCTs by:
1. Searching the Sexually Transmitted InfectionsCochrane Review
Group’s Specialized Register, which includes RCTs and controlled
clinical trials, from 1944 to 2012, located through:
• Electronic searching in MEDLINE, EMBASE and
CENTRAL; and
• Online handsearching in those journals not indexed in
MEDLINE or EMBASE, according to the journals’ master list of
the STI Cochrane Review Group.
2. Searching trials registers:
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) portal (http://apps.who.int/
trialsearch/) (searched 27 May 2015);
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• ClinicalTrials.gov (http://clinicaltrials.gov/) (searched 27
May 2015).
3. Searching for gray literature in the System for Infor-
mation on Grey Literature in Europe “OpenGrey” (http://
www.opengrey.eu/) (searched 27 May 2015).
4. Contacting authors of all RCTs identified by other methods. A
comprehensive list of RCTs included in the review along with the
criteria for considering studies was sent to the first author of each
included study, with a request for any additional studies, published
or unpublished, that might be relevant.
5. Handsearching conference proceeding abstracts from the fol-
lowing events:
• The International Society for Sexually Transmitted Diseases
Research - ISSTDR (http://www.isstdr.org/): 2007, 2009 and
2011.
• The British Association for Sexual Health and HIV -
BASHH (http://www.bashh.org/): 2004, 2006, 2007 and 2009.
• International Congress on Infectious Diseases - ICID (
http://www.isid.org/): 2010 and 2012.
• The International Union against Sexually Transmitted
Infections - IUSTI (http://www.iusti.org/): 2011 and 2012.
• International Society for Infectious Diseases - ISID (http://
www.isid.org/): 2011.
• International Meeting on Emerging Diseases and
Surveillance - IMED (http://www.isid.org/): 2007, 2009 and
2011.
• Interscience Conference on Antimicrobial Agents and
Chemotherapy - ICAAC (http://www.icaac.org/): 2011 and
2012.
• The International Federation of Gynecology and Obstetrics
- FIGO (http://www.figo2012.org/home/): 2012.
6. Handsearching previous systematic reviews and other relevant
publications on the same topic.
7. Handsearching reference lists of all relevant RCTs identified by
other methods.
Data collection and analysis
Selection of studies
Assessment of eligibility of studies was conducted by three authors
separately (LF, JA, PV) who examined each title and abstract to
exclude irrelevant reports. The full-length articles of the selected
titles or abstracts were screened against the inclusion criteria. Mul-
tiple reports of the same study were linked together. We resolved
disagreements by discussion. If there was still a disagreement, a
fourth author made the final decision (HG).
Data extraction and management
PV, JA and LF extracted data from each of the included trials
independently using a data extraction form designed by the au-
thors. Differences were resolved by discussion and the consensus
entered into a new form. EA checked the completed consensus
form against the original papers. The data extraction form was pi-
lot tested using one of the included studies. If there were multiple
publications relating to the same study, we extracted data from
all reports into a single data extraction form. If items reported
in different publications were inconsistent, we used the primary
publication as the source document. The primary publication was
that which reported the primary outcome.
We extracted the following data:
• Methodology: trial design, identified population, sample
size, location of the study, blinding and statistical methods;
baseline information on the participants in order to have
comparable intervention and control groups at entry; methods
used to generate random allocation, methods used to maintain
allocation concealment; and use of intention-to-treat analysis.
• Participants: number, source, age, gender, inclusion and
exclusion criteria, recruitment site, previous investigations and
treatments, co-morbidities, history of STIs, use of contraception,
number of sexual partners, number of participants enrolled,
randomized, excluded after randomization, and analyzed.
• Interventions: type of testing carried out in home-based
testing group and intervention described in control group;
instructions about how to collect the specimen; processes
involved in patient- or provider-collected samples; devices used
for taking the specimen; specimen transport conditions; processes
for handling the sample at the site where it will be processed;
accuracy of the underlying tests; processes for sending results to
providers; processes for informing patients about their test results
and ensuring follow-up for treatment; antibiotic treatment;
notification and treatment of sexual partner(s); time to follow-up
and results; other interventions in the groups under evaluation.
• Outcomes: number of individuals tested, diagnosed and
treated for CT and NG; number of individuals treated and
having evidence of freedom from infection during period of
RCT; positive test prevalence (number of infections identified/
number of subjects tested); number of individuals who
completed testing for CT or NG; number of infections treated;
number of sexual partners receiving treatment; number of
individuals not tested at the end (sample was not obtained);
adverse effects of testing; barriers to testing; feasibility;
acceptability; number of patients receiving treatment, positive
test prevalence; costs.
• Reported funding sources and conflicts of interest.
• Ethical issues: use of signed informed consent and ethics
approval.
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We extracted the data and then we checked and entered them into
Review Manager 5 (RevMan) software.
Assessment of risk of bias in included studies
Two review authors (LF, PV) independently assessed the risk of bias
within each included study by addressing six specific domains, us-
ing the ’Risk of bias’ assessment tool (Higgins 2011). We assessed:
sequence generation; allocation concealment; blinding of partici-
pants, providers and outcome assessors; completeness of outcome
data; selective outcome reporting; and other potential sources of
bias. LF and PV compared the results and in case of disagreement
between them, we made the decision by consensus.
For each included study, the review authors made a decision by
assigning a judgement of ’low risk’ of bias, ’high risk’ of bias, or
’unclear risk’ of bias for the following domains:
(1) Random sequence generation (checking for possible
selection bias)
For each included study we described themethod used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk (any truly random process, e.g. random number
table; computer random number generator);
• high risk (any non-random process, e.g. odd or even date of
birth; hospital or clinic record number);
• unclear risk, if the trial is described as randomized, but the
method used for the allocation sequence generation is not
described.
(2) Allocation concealment (checking for possible selection
bias)
For each included study we described the method used to conceal
the allocation sequence in sufficient detail and determine whether
intervention allocation could have been foreseen in advance of, or
during recruitment, or changed after assignment.
We assessed the methods as:
• low risk (e.g. telephone or central randomization;
consecutively numbered sealed opaque envelopes);
• high risk (open random allocation; unsealed or non-opaque
envelopes; alternation; date of birth);
• unclear risk, if the trial is described as randomized but the
method used to conceal the allocation is not described.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We restricted assessment of blinding to blinding of outcome as-
sessors, since it is not possible to blind participants and personnel
to strategy of sample collection.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received.We assessed blinding separately for subjective
outcomes (adverse effects of testing, barriers to testing, feasibility,
acceptability) and objective outcomes (being tested, diagnosed,
treated and having evidence of freedom from infection for CT and
NG, positive test prevalence, number of sexual partners receiving
treatment, number of individuals not tested at the end, costs).
We assessed methods used to blind outcome assessment as low,
high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for short-term out-
comes (being tested, being diagnosed, positive test prevalence, ad-
verse effects of testing, barriers to testing, feasibility, acceptability)
and long-term outcomes (treated and having evidence of freedom
from infection, number of individuals not tested, number of sex-
ual partners receiving treatment, costs), the completeness of data
including attrition and exclusions from the analysis. We stated
whether attrition and exclusions were reported and the numbers
included in the analysis at each stage (compared with the total
randomized participants), reasons for attrition or exclusion where
reported, and whether missing data were balanced across groups
or were related to outcomes. Where trial authors reported or sup-
plied sufficient information, we re-included missing data in the
analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomization, > 20% of missing data);
• unclear risk of bias.
(5) Selective reporting bias (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where not all of the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
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include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
have about other possible sources of bias. We assessed whether
each study was free of other problems that could put it at risk of
bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). With
reference to (1) to (6) above, we assessed the likely magnitude and
direction of the bias and whether we considered it is likely to im-
pact on the findings. We explored the impact of the level of bias
through undertaking sensitivity analyses - see Sensitivity analysis.
We created a ’Risk of bias’ table to report on the risk of bias in
included studies.
Measures of treatment effect
We expressed dichotomous outcomes as the risk ratio (RR) with
95% confidence intervals (CI).
Unit of analysis issues
Cluster-randomized trials
The unit of analysis for most trials was the individual. Ostergaard
1998 employed cluster randomization and did not take the unit
of allocation and cluster design into account in their analysis. We
asked the authors for more information but we did not receive
a reply. The authors analyzed data from individuals rather than
the cluster. We therefore extracted the average cluster size (524)
and the number of clusters randomized (17), and used an intra-
cluster correlation coefficient (ICC) of 0.00119, obtained from a
published external source (Ukoumunne 1999). We followed the
methods stated in the Cochrane Handbook for Systematic Reviews
of Interventions to analyze the data (Higgins 2011). If heterogene-
ity among the included studies seemed to be meaningful and the
effect of the intervention was strongly associated with the unit of
randomization, we examined the results after excluding the clus-
ter-randomized trial.
Dealing with missing data
We reported the percentage of observations with missing data in
each included trial. We performed sensitivity analysis including or
excluding trials with high levels of missing data to explore the im-
pact of missing data in the overall assessment of the intervention.
For all outcomes, we analyzed results with all participants in the
group to which they were allocated, excluding only participants
with missing outcome data. The denominator for each outcome
in each trial was the number randomized minus any participants
whose data are known to be missing. We communicated with the
authors of the included studies to obtain missing data.
Assessment of heterogeneity
We explored heterogeneity by visual inspection of the forest plot
and with an I² and tau statistic and Chi² tests (Higgins 2003). We
judged heterogeneity as considerable if I² was greater than 50% or
if the P value in the Chi² test was less than 0.10.
Assessment of reporting biases
We did not find a sufficient number of studies (more than 10) to
include in the meta-analysis, so we did not produce funnel plots
to investigate reporting biases.
Data synthesis
We used narrative and descriptive synthesis to explore the results
from the third group of secondary outcomes. We performed sta-
tistical analysis using Review Manager 5 (RevMan). Data were
pooled using a fixed-effect model or random-effects model, as ap-
propriate, depending on the level of heterogeneity. The fixed-ef-
fect model of meta-analysis was applied if the studies estimated
the same intervention effect. This was conducted with the aim of
combining the results. Otherwise, if clinical and statistical hetero-
geneity were substantial, then we used a random-effects model to
summarize the effects of the intervention. The results were pre-
sented as the summary RR (95% CI) with I² and tau² statistic.
The Mantel-Haenszel (M-H) method was used to conduct meta-
analysis of dichotomous data. The inverse variance (IV) method
was used for continuous data.
’Summary of findings’ table
We summarized the results for the main comparison of home-
based versus clinic-based specimen collection for CT and NG
detection in ’Summary of findings’ tables (Schünemann 2011a).
We used the GRADE approach to assess the quality of evidence
in relation to each outcome included (Schünemann 2011b); and
used GRADE profiler (GRADEpro) software to import data from
RevMan 5 to create ’Summary of findings’ tables (RevMan). We
report the following main outcomes in the ’Summary of findings’
table, in terms of their importance for decision-making:
11Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae
infections (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Index case management;
• Proportion of individuals tested;
• Positive test prevalence;
• Adverse effects of testing;
We downgraded the quality of evidence depending on the pres-
ence of the five GRADE considerations (study limitations; incon-
sistency of results; indirectness of evidence; imprecision; and pub-
lication bias).
Subgroup analysis and investigation of heterogeneity
We planned to perform a subgroup analysis to explore heterogene-
ity according to:
• Sex of the patient;
• Returning specimens by mail or in person, which might
influence intervention adherence;
• Notification and treatment at clinic or sent to home, which
might be related to adherence and accessibility to treatment and
diagnosis;
• Level of sexual behavior risk of the study population
(groups at high risk of CT or NG: patients whose partners have a
diagnosis of CT and NG, patients who are undertaking repeat
testing following treatment for CT or NG, sex workers, people
with HIV infection, MSM);
• Pregnant women: pregnancy could influence adherence to
diagnosis, treatment and follow-up;
• Adolescent: age below 18 years might be related to poor
adherence to diagnosis, treatment and follow-up.
For fixed-effectmodels based on inverse variancemeta-analysis, we
assessed differences between subgroups by interaction tests (Deeks
2001). For random-effectsmodels we performed stratified analyses
and used meta-regression to estimate the ratio of risk ratios (RRR,
with 95%CI), comparing studies with the characteristic of interest
with those without (using the command “metareg” in Stata).
We performed one subgroup analysis that was not pre-specified in
the protocol of this review. We examined the intervention effect
according to the use of reminders. Intervention effects might have
differed between trials that did or did not use reminders to increase
test uptake.
Sensitivity analysis
We planned to perform sensitivity analysis taking into account the
possibility that the quality of the studies, the inclusion of cluster
RCTs, different ICCs in the analysis of cluster-randomized trials
and the variation in the imputed values for missing data may
have influenced the results. We performed sensitivity analysis for
outcomes with statistical heterogeneity using different statistical
models, that is, fixed-effect and random-effects models.
R E S U L T S
Description of studies
Results of the search
The search of electronic databases on 27 May 2015 yielded 730
records, of which 197 were duplicate records. We reviewed the
titles and abstracts of 533 records and discarded 508 records. We
examined the full text of the remaining 25 records.We included 10
published studies that met our inclusion criteria (Andersen 1998;
Ostergaard 1998; Ostergaard 2003; Cook 2007; Jones 2007;
Lippman 2007;Graseck 2010;Xu2011;Reagan 2012;Götz 2013;
see Figure 1). The search of other sources did not identify any
new records. We excluded 12 full-text articles (see Characteristics
of excluded studies). In addition, we excluded trials by Andersen
2002, Scholes 2007 and Klovstad 2013 because the comparison
was usual care, rather than clinic-based specimen collection from
all patients in a clinic that met the criteria forChlamydia trachoma-
tis (CT) or Neisseria gonorrhoeae (NG) testing.
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Figure 1. Study flow diagram.
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One trial (Apoola 2009) was classified as ’awaiting classification’
because outcome data were not available (see Characteristics of
studies awaiting classification). We contacted the study authors,
but they did not provide information. We found two ongoing
studies as a result of the search (De Barbeyrac 2013; Smith 2014;
see Characteristics of ongoing studies).
Included studies
The 10 RCTs included 10,479 participants (see Characteristics
of included studies). These trials were three from Denmark
(Andersen 1998; Ostergaard 1998; Ostergaard 2003), four from
USA (Cook 2007; Graseck 2010; Xu 2011; Reagan 2012), and
one each from Netherlands (Götz 2013), Brazil (Lippman 2007),
and South Africa (Jones 2007). In most trials, recruitment was
based in community clinics (Cook 2007; Jones 2007; Lippman
2007; Graseck 2010; Reagan 2012). Two trials enrolled partici-
pants from STI clinics (Xu 2011; Götz 2013), two from general
practices (Andersen 1998; Ostergaard 2003), and one recruited
from 17 high schools in a cluster RCT (Ostergaard 1998). Six
trials carried out a valid method for sample size calculation in ad-
vance (Cook 2007; Jones 2007; Graseck 2010; Xu 2011; Reagan
2012; Götz 2013). In the study by Xu 2011 the authors described
their two RCTs but we considered this as a single trial that used
stratified randomization. All included studies were published in
English.
Participants
Five trials evaluated patients having high risk of STIs; two trials
were conducted among patients with previous CT infection and
evaluated retesting (Xu 2011; Götz 2013), two trials (Andersen
1998; Ostergaard 2003) evaluated testing of sexual partners of CT
positive individuals (one ofwhich includedmale partners of female
index patients only, Andersen 1998), and one included women
with a recent diagnosis of STI or an increased risk of acquiring a
STI (Cook 2007). Five trials included women only (Cook 2007;
Jones 2007; Lippman 2007; Graseck 2010; Xu 2011), and two
includedmenonly (Andersen 1998;Reagan 2012). The remaining
trials included both male and female participants (Ostergaard
1998;Ostergaard 2003;Götz 2013). The trials included3138men
and 7341 women. Götz 2013 did not report the sex of participants
according to the group assignment.
Interventions
In three trials, authors stated that they allocated participants to
home-based or clinic-based specimen collection, analysed speci-
mens, gave results and provided antibiotic treatment (Lippman
2007; Graseck 2010; Reagan 2012). Graseck 2010 also reported
that women were given antibiotics for all sexual partners.
In five trials, participants took their own swabs in both the home-
and clinic-based groups (Jones 2007; Lippman 2007; Graseck
2010; Reagan 2012; Götz 2013). In the other five trials, clinic
staff took the specimens in the clinic-based group (Andersen 1998;
Ostergaard 1998; Ostergaard 2003; Cook 2007; Xu 2011).
For trials that included women only, three compared home-col-
lected vaginal swabs with vaginal swabs collected at a clinic (Jones
2007; Lippman 2007; Graseck 2010). The other two trials com-
pared home-collected vaginal swabs with an appointment to re-
turn to clinic for testing but did not state the clinic procedures for
specimen collection (Cook 2007; Xu 2011).
For trials that included men: Andersen 1998 evaluated home-
collected first catch urine specimen versus a referral to a clinic
for urethral specimen collection. Reagan 2012 compared home-
collected urine specimens with urine specimens collected at the
clinic.
For trials that enrolled bothwomen andmen, one evaluated home-
collected urine specimens for men and vaginal swabs for women
versus an invitation to attend the clinic where the same speci-
men types were collected (Götz 2013). Ostergaard 1998 com-
pared home-collected specimens from women (two urine speci-
mens and a vaginal flush specimen) and men (first catch urine
specimen) with an offer of clinic-based sampling with unspecified
specimen types. Ostergaard 2003 sent specimen collection kits to
index patients with chlamydia and assigned them at random to
telling partners to collect specimens at home and mail them to the
laboratory, or bringing the specimen kit to a clinic and providing
the specimen at the clinic. Female partners collected vaginal flush
specimens and male partners provided first catch urine specimens.
Participants in the home-based specimen collection groups sent
their samples to the laboratory bymail in all trials but one, inwhich
they brought their home-taken sample to the clinic for laboratory
testing (Lippman 2007).
All trials used NAATs for diagnosis. Five trials tested specimens for
CT infection only (Andersen 1998; Ostergaard 1998; Ostergaard
2003; Xu 2011; Götz 2013). Three trials tested for CT and NG
(Cook 2007;Graseck 2010;Reagan 2012); and two trials tested for
CT, NG and Trichomonas vaginalis (TV) (Jones 2007; Lippman
2007).
Some trials used reminders to encourage adherence to study in-
terventions (Jones 2007; Lippman 2007; Xu 2011; Götz 2013).
Andersen 1998, Ostergaard 1998 and Ostergaard 2003 did not
report the use of reminders. Reagan 2012 did not use reminders
but gave a monetary incentive of $10 gift card to the participants.
Cook 2007 and Graseck 2010 explicitly stated that they did not
use any kind of reminder. In this review, for the secondary out-
come ’proportion of individuals tested’, we classified Cook 2007
as having used reminders, because the authors report the propor-
tion of participants who completed at least one test during the two
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year trial period, which included three invitations to be tested.
Outcomes
The prespecified primary outcomes were not completely evaluated
in the included trials. None of the included trials had an author-
defined outcome that fulfilled our definition of index case man-
agement. Only three trials allowed the outcome of index case man-
agement to be assessed and none specified the antibiotic treatment
used (Lippman 2007; Graseck 2010; Reagan 2012). The evalua-
tion and reporting of treatment of infected participants were not
clearly stated in the remaining trials (Andersen 1998; Ostergaard
1998; Ostergaard 2003; Cook 2007; Jones 2007; Xu 2011; Götz
2013). No trials reported adverse effects of testing.
In the first set of secondary outcomes, all trials reported the pro-
portion of individuals tested. This was the primary outcome stated
by the authors of these trials. The authors of all butCook 2007 also
reported the positive test prevalence. Cook 2007 reported rates of
positive tests per 100 woman-years of follow-up. The number of
infected individuals receiving treatment was mentioned in only
three trials (Lippman 2007; Graseck 2010; Reagan 2012).
For the second set of secondary outcomes, no trial reported the
proportion of sexual partners receiving treatment or measured the
proportion of infections cured. Although the participants in two
trials were sexual partners of index cases the investigators did not
evaluate themanagement of other sexual partners (Andersen1998;
Ostergaard 2003).
Outcomes in the third set of secondary outcomes were evaluated
in four trials. Two trials described the results of surveys and re-
ported information about feasibility and acceptability (Jones 2007;
Lippman 2007). We found an economic evaluation of the trial by
Cook 2007 (Smith 2007). This was a cost comparison without
a cost-effectiveness analysis. Graseck 2010 evaluated barriers to
testing in participants who did not complete testing.
Excluded studies
We excluded 12 full-text articles (Characteristics of excluded
studies). Six articles were not RCT (Gray 1998; Van Valkengoed
2002; Sparks 2004; Buhrer-Skinner 2011; Emmerton 2011; Falk
2014; ). Four studies did not evaluate the comparison specified
in the protocol because participants in the control group were
tested only if they had symptoms (Andersen 2002; Scholes 2007;
Andersen 2011; Klovstad 2013). Ostergaard 1999 was a duplicate
from Ostergaard 1998 in Danish. Ostergaard 2000 reported the
follow-up to the primary report (Ostergaard 1998).
Risk of bias in included studies
The risk of bias for each included study is presented in the ’Risk of
bias’ table in the section Characteristics of included studies. Figure
2 and Figure 3 illustrate the summary of risk of bias assessment in
included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Random sequence generation
Six trials adequately reported a random sequence generation
method. Of these trials, three used computer-generated, blocked
randomization (Cook 2007; Lippman 2007; Xu 2011); and three
trials used computer-generated random number lists (Graseck
2010; Reagan 2012; Götz 2013). One trial reported that the date
of birth of index patient was used to allocate participants to inter-
vention and control groups, and was judged to be at high risk of
bias (Andersen 1998). In the remaining included trials the random
sequence generation was unclear (Ostergaard 1998; Ostergaard
2003; Jones 2007).
Allocation concealment
Six trials reported adequate allocation concealment. Of these, four
trials reported the use of sealed, sequentially numbered envelopes
(Cook 2007; Jones 2007; Lippman 2007; Xu 2011); one trial
reported the use of a central randomization (Ostergaard 2003);
and in one trial the participants had no knowledge of allocation
until time of testing (Graseck 2010).
In the four remaining, the methods used for allocation conceal-
ment were not adequately described, making the risk of selection
bias at entry unclear (Andersen 1998; Ostergaard 1998; Reagan
2012; Götz 2013).
Blinding
Blinding of participants and personnel (performance bias)
It is not possible to blind participants and personnel to dif-
ferent specimen-collection methods (Andersen 1998; Ostergaard
1998; Ostergaard 2003; Cook 2007; Jones 2007; Lippman 2007;
Graseck 2010; Xu 2011; Reagan 2012; Götz 2013). Knowledge
of the assigned strategy might influence adherence to testing and
intervention compliance, so we judged all trials as being at high
risk of performance bias.
Blinding of outcome assessment (detection bias)
Subjective outcomes
Seven trials did not report subjective outcomes (adverse effects
of testing, barriers to testing, feasibility, acceptability) and were
judged as being at unclear risk of detection bias (Andersen 1998;
Ostergaard 1998; Ostergaard 2003; Cook 2007; Xu 2011; Reagan
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2012; Götz 2013). One trial evaluated barriers to testing without
blinding and was judged as being at high risk of detection bias
(Graseck 2010). Two trials reported feasibility and acceptability
outcomes; Jones 2007 was unblinded and judged as being at high
risk of detectionbias, andLippman 2007 didnot provide sufficient
information so was judged as unclear risk of bias.
Objective outcomes
All trials reported some objective outcomes. Five trials did not
provide sufficient information about blinding of outcome asses-
sors so the risk of bias was unclear (Andersen 1998; Ostergaard
1998; Ostergaard 2003; Lippman 2007; Xu 2011). One trial was
judged as low risk of bias since outcome assessors were blinded to
participants assignment (Cook 2007). Four trials were unblinded
and judged as being at high risk of bias (Jones 2007; Graseck 2010;
Reagan 2012; Götz 2013).
Incomplete outcome data
Short-term outcomes
With respect to short-term outcomes (being tested, being diag-
nosed, positive test prevalence, adverse effects of testing, barri-
ers to testing, feasibility, acceptability), only one trial had an at-
trition rate of less than 20 % (Lippman 2007); 96% of partici-
pants were tested in this study, so was judged as low risk of bias.
Eight trials were at high risk of attrition bias with more than 20%
lost to follow-up and imbalances between groups (Andersen 1998;
Ostergaard 1998; Ostergaard 2003; Xu 2011;Reagan 2012; Götz
2013). Attrition rates in Cook 2007 and Jones 2007 were high
but balanced in the intervention groups, so we judged these trials
as being at unclear risk of attrition bias. In Graseck 2010 they had
tests for 151/268 in the home-based group and medical records
or a specimen from 163/280 in the clinic-based group; this was
judged as low risk of bias.
Long-term outcomes
For long-term outcomes (receiving treatment, evidence of freedom
from infection, number of individuals not tested, number of sexual
partners receiving treatment, costs) all trials reported the number
of individuals not tested and had attrition rates greater than 20%,
except for Lippman 2007where 96%completed the test andwhere
the use of reminders was intense. No trial reported on negative
test results 12 months after the treatment or the number of sexual
partners receiving treatment so all had an unclear risk of bias (
Andersen 1998; Ostergaard 1998; Ostergaard 2003; Cook 2007;
Jones 2007; Lippman 2007; Graseck 2010; Xu 2011; Reagan
2012; Götz 2013).
Selective reporting
We searched for trial protocols to assess reporting bias. If the trial
protocol was not accessible, we looked for selective reporting in
trials by searching for reports of the primary outcome in theMeth-
ods and the Results sections of the report. Protocols were avail-
able for four trials (Cook 2007; Graseck 2010; Xu 2011; Reagan
2012). We judged these four trials to have a low risk of reporting
bias because the primary outcome stated in the protocol was re-
ported in the trial result section (Graseck 2010; Xu 2011; Reagan
2012). For six trials the trial protocol was not available and it was
unclear if it had been published; all reports did not clearly state
the expected outcomes and therefore were judged as unclear risk
of bias (Andersen 1998; Ostergaard 1998; Ostergaard 2003; Jones
2007; Lippman 2007; Götz 2013).
Other potential sources of bias
Four trials used reminders as part of their management strategy,
which might increase the number of participants completing the
intervention (Jones 2007; Lippman 2007; Xu 2011; Götz 2013).
Participants in two trialswere chlamydia positive patients, inwhich
the study objective was to evaluate re-testing (Götz 2013; Xu
2011); and in another two trials the population objective was
sexual partners of CT positive index patients (Andersen 1998;
Ostergaard 2003). In Cook 2007 they recruited women with a
recent diagnosis of CT, NG or TV. In these trials participants are
part of a selective population where the adherence to intervention
might be influenced by their previous status. We found that the
cluster-RCTbyOstergaard 1998 didnot take the unit of allocation
and cluster design into account in their analysis.
Effects of interventions
See: Summary of findings for the main comparison Home-
based compared with clinic-based specimen collection for CT and
NG
See Summary of findings for the main comparison
Home-based specimen collection versus clinic-based
specimen collection in the management of CT and
NG
Ten trials with 10,479 participants compared home-based versus
clinic-based specimen collection. Not all trials provided data for
each outcome analysis. The data were obtained from published
reports and it was not possible to obtain additional information
from authors. Harms of testing, which was a primary outcome,
was not evaluated in any trial.
Primary outcomes
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1.1 Index case management
We extracted data from three studies about the complete manage-
ment strategy, defined as participants who were tested, diagnosed
and treated (Lippman 2007; Graseck 2010; Reagan 2012). A total
of 1566 participants (1366 women and 200 men) were enrolled
in these trials; 45 CT or NG infections were diagnosed amongst
778 participants assigned to collect specimens at home and 51 CT
or NG infections were diagnosed amongst participants assigned
to clinic-based specimen collection. Graseck 2010 reported that
all women with positive test results received treatment. Lippman
2007 reported that one woman did not receive treatment, but did
not say in which arm of the trial. We conducted the primary anal-
ysis assuming that the untreated woman was in the home-based
group and repeated it assuming she was in the clinic-based group.
Reagan 2012 reported that all men with positive test results re-
ceived treatment.
Meta-analysis of three trials showed no difference in the propor-
tions with index case management strategy between home-based
(45/778, 5.8%) and clinic-based (51/788, 6.5%) groups (RR0.88,
95% CI 0.60 to 1.29; participants = 1566; studies = 3; I² = 0%,
tau 0.00; Analysis 1.1; Figure 4). The result was almost the same
when the untreated woman in Lippman 2007 was allocated to the
clinic-based arm (RR 0.92, 95% CI 0.63 to 1.35). We judged the
quality of evidence as moderate as a result of high risks of detection
and attrition bias in the included studies (Summary of findings
for the main comparison).
Figure 4. Forest plot of comparison: 1 Home-based vs clinic-based specimen collection for CT and NG,
outcome: 1.1 Index case management.
Secondary outcomes
1.2 Proportion of individuals tested
All included studies evaluated the proportion of individuals tested.
The proportions of participants tested varied widely between stud-
ies. Amongst participants assigned to home-based specimen col-
lection, uptake ranged from 30% (95% CI 26% to 33%, 189/
639) of women invited to be re-tested after treatment for CT or
NG in the USA (Xu 2011, RR 1.61, 95%CI 1.32 to 1.97) to 96%
(95% CI 93% to 98%, 393/410) of women invited to have a first
time test for CT, NG or TV in Brazil (Lippman 2007, RR 0.99
95% CI 0.97 to 1.02). Amongst participants assigned to clinic-
based specimen collection, uptake ranged from 6% of high school
students who were advised to have a CT test at a physician’s office
in Denmark (Ostergaard 1998); to 97% (95% CI 94% to 98%,
394/408) invited to have a first time test for CT, NG or TV in
Brazil (Lippman 2007).
There was substantial heterogeneity between the results of in-
dividual studies and we did not pool the results (participants =
10479; studies = 10; I² = 100%, tau 2.15; Analysis 1.2; Figure 5).
In eight of 10 studies the proportion of participants tested was
higher with home-collected specimens than clinic-collected speci-
mens (Andersen 1998; Ostergaard 1998; Ostergaard 2003; Cook
2007; Graseck 2010; Xu 2011; Reagan 2012; Götz 2013); and
in two studies there was no difference in test uptake (Jones 2007;
Lippman 2007). The largest difference in uptake was in the trial
byOstergaard 1998 (RR 20.55, 95%CI 15.08 to 28.00). In a sen-
sitivity analysis that excluded this study, heterogeneity remained
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extremely high (I² = 99%, tau 0.4) with a RR from random ef-
fects meta-analysis of 1.56 (95% CI 1.03 to 2.38). We judged the
quality of evidence as low as a result of high risk of selection and
attrition bias, and inconsistency in the included studies (Summary
of findings for the main comparison).
Figure 5. Forest plot of comparison: 1 Home-based vs clinic-based specimen collection for CT and NG,
outcome: 1.2 Proportion of individuals tested.
1.3 Proportion of individual tested grouped by sex
In both women and men, a higher proportion of participants
returned specimens in the home-based than clinic-based group
(Analysis 1.3). Between-trial heterogeneity remained high, how-
ever, in both women (I² = 100%, tau 2.04) and men (I² = 95%,
tau 0.94). Using meta-regression, there was inconclusive evidence
that the effect size differed between women and men (RRR 0.72.
95% CI 0.40 to 1.31, I² = 93%).
1.4 Proportion of individual tested grouped by STI risk
When trials were stratified according to the risk of participants
being infected with an STI (high or low), more participants in
the home-based group than in the clinic-based group returned
specimens in both subgroups (Analysis 1.4). Between-trial hetero-
geneity remained high (high risk participants I² = 75%, tau 5.93;
low risk participants I² = 100%, tau 0.04). Using meta-regression,
there was no difference in the effect size between groups (high risk
versus low risk RRR 0.88, 95% CI 0.27 to 2.85, I² = 98%).
1.5 Proportion of individual tested grouped by method of
returning specimens
There was only one trial in which participants returned home-
collected specimens to the clinic in person. Amongst trials inwhich
home-collected specimens were returned by post, heterogeneity
remained extreme (I² = 100%, tau 0.64; Analysis 1.5). In meta-
regression, the effect sizes differed somewhat (RRR 0.47, 95% CI
0.07 to 2.96, I² = 96%), but confidence intervals were very wide.
1.6 Proportion of individual tested grouped by use of
reminders
When trials were stratified according to the stated use of reminders
or not, more participants In the home-based group than in the
clinic-based group returned specimens in both subgroups (Analysis
1.6). In two trials that did not use reminders, the findings were
statistically consistent (RR 1.62, 95% CI 1.39 to 1.89; partici-
pants = 748; I² = 0%, tau 0.00). In five trials that used reminders,
heterogeneity remained high (I² = 98%, tau 0.23). In meta-regres-
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sion, there was inconclusive evidence that the effect sizes differed
between trials that used reminders versus trials that did not (RRR
0.81, 95% CI 0.48 to 1.37, I² = 90%).
1.7 Positive test prevalence
Nine studies reported numbers of positive test results as a pro-
portion of participants tested (Andersen 1998; Ostergaard 1998;
Ostergaard 2003; Jones 2007; Lippman 2007; Graseck 2010; Xu
2011; Reagan 2012; Götz 2013). Cook 2007 reported rates of
positive tests per 100 woman-years of follow-up (20.4 for home-
collected specimens versus 24.1 for clinic-collected specimens, P
= 0.28) and we did not combine these with the outcomes reported
as proportions.
The proportions of positive test results varied between trials. The
lowest proportions were in trials that enrolled participants from
a cohort study of contraceptive practices in women in the US (
Graseck 2010, 2.3%); high schools inDenmark (Ostergaard 1998,
4.4%); and community-based efforts with men in the US (Reagan
2012, 5.8%). The highest proportions were in patients who had
sex partners with CT or NG (Andersen 1998, 30%; Ostergaard
2003, 43%).
Meta-analysis of nine trials showed a lower proportion of posi-
tive CT or NG test results with home-based (240/2074, 11.6%)
thanwith clinic-based (179/967, 18.5%) specimen collection (RR
0.72, 95% CI 0.61 to 0.86; participants = 3041; studies = 9; I²
= 0%, tau 0.00); Analysis 1.7; Figure 6). We used a fixed-effect
model, owing to the low between-study heterogeneity (I² < 50%).
A sensitivity analysis that excluded the cluster-randomized trial by
Ostergaard 1998 did not change the results (RR 0.73, 95% CI
0.61 to 0.87; participants = 2201; studies = 8; I² = 0%, tau 0.00).
We judged the quality of evidence as moderate as a result of high
risk of biases in the included studies (Summary of findings for the
main comparison).
Figure 6. Forest plot of comparison: 1 Home-based vs clinic-based specimen collection for CT and NG,
outcome: 1.7 Positive test prevalence.
1.8 Proportion of infections treated
Only three of the trials included in the analysis of primary out-
comes clearly stated that patients with positive test results were
treated. Lippman 2007 reported that all but one woman in the
home group was not treated. We did not perform a meta-analysis
to analyse these results.
1.9 Process outcomes
We found four studies that addressed issues related to adher-
ence and compliance (Jones 2007; Lippman 2007; Graseck 2010;
Reagan 2012). Reagan 2012 reported on barriers to testing during
a follow-up survey with 129 men. They found that 16% did not
complete the testing due to lack of health insurance, 12% because
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of the cost of screening, and 9% because of difficulties with trans-
portation to the clinic. Participants also reported the following
subjective concerns: inconvenience of screening, 7%; bad experi-
ence with previous STI test, 5%; concern about the safety of the
test, 5%; concern about privacy if the test result were positive, 5%;
and disapproval by family members about testing, 2%. Graseck
2010 reported, in a survey with 207 women, that the main reason
for not completing the test was “forgot” in 49% in the home-based
group and 24% in the clinic group.
Feasibility and acceptability were evaluated by Jones 2007 and
Lippman 2007. These two studies shared almost the same proto-
col, but the trial was performed in different countries. Lippman
2007 analysed data from 787 women that answered a question-
naire in Brazil. Women collected their own samples in both home-
and clinic-based groups and 96% of women in both groups found
self-sample collection to be comfortable and easy. A survey that
included 244 women in the study by Jones 2007 in South Africa
found that 86% of women in the home-based group and 96% in
clinic-based group found self-sample collection very easy. Accept-
ability, evaluated as feeling pain during sampling, was reported in
17% of home-based group and 12% of the clinic-based group.
1.10 Economic outcomes
Smith 2007 examined the direct and indirect costs associated with
home- and clinic-based specimen collection forCT andNG, using
data gathered in the trial by Cook 2007. The outcome was the
number of completed tests per participant. Direct costs were $49
per test in clinic-based group and indirect costs were $62 per test,
while in the home-based group they reported that the cost was
$25 per test.
Subgroup analysis and investigation of heterogeneity
We did not conduct subgroup analyses or sensitivity analyses for
the primary outcome because only three trials provided results.
The findings of these trials were statistically consistent.
The findings of subgroup analyses for the outcome “proportion
of individuals tested” are reported in paragraphs 1.3 to 1.6, with
the overall analysis of this secondary outcome .
We did not perform subgroup analyses for “notification and treat-
ment at clinic or sent to home“, ”pregnant women“ and ”adoles-
cents” because none of the included trials reported information
about these subgroups.
D I S C U S S I O N
Summary of main results
Ten RCTs including 10,479 participants (7341 women and 3138
men) fulfilled the inclusion criteria and were included. Three tri-
als (1566 participants) assessed the primary outcome. There was
no evidence of a difference in index case management between
home-based and clinic-based specimen collection as part of a case
management strategy for Chlamydia trachomatis (CT) or Neisseria
gonorrhoeae (NG). We judged the level of evidence as moderate.
Harms of testing, which was a primary outcome, were not evalu-
ated in any trial.
All included trials compared the proportion of individuals tested.
Between-trial heterogeneity was very high so we did not pool the
results, but uptake of testing was higher with home-collected than
with clinic-collected specimens in eight of 10 included trials. Het-
erogeneity was not explained by sex of the patient, level of STI
risk, procedure for returning specimens or use of reminders. We
judged the risk of bias for this secondary outcome as high and the
quality of evidence as low.
Nine trials (3041 participants) compared the positive test preva-
lence and there was evidence of a lower proportion of positive tests
in participants assigned to home-based specimen collection. We
judged the risk of bias for this secondary outcome as high and the
quality of evidence as moderate.
Four trials evaluated outcomes about adherence and compliance
with the use of home-collected specimens. Self-sampling was re-
ported to be comfortable and easy both at home or in a clinic.
Overall completeness and applicability of
evidence
The evidence that we found about the use of home-collected spec-
imens to improve the outcomes of case management for CT and
NG infections was incomplete for two reasons. First, owing to an
absence of studies, we could not assess the effect of the interven-
tion on the complete pathway for comprehensive case manage-
ment (UNAIDS 1999). Successful case management for bacterial
STIs does not stop with providing treatment because of the risk to
the patient of re-infection by a known but untreated sex partner.
A biological outcome, such as testing negative for CT or NG 12
months after treatment would be much more robust as an effec-
tiveness outcome, but none of the RCTs that we assessed reported
on sexual partner management or repeated tests 12 months after
the intervention. Second, only three of the 10 included trials re-
ported on the intermediate outcome that we chose as our primary
outcome. Even so, the RCTs included did not specify the antibi-
otics used for treatment.
The body of evidence about the use of home-collected specimens
for STI testing comprises mainly RCTs that measured only the
proportion of people that returned a specimen for testing. Test
uptake is not a clinically relevant outcome because it does not
give any information about the presence of an STI or whether the
infection was successfully treated. Secondary outcomes like test
uptake and the positive test results help to interpret the primary
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outcome. Test uptake was extremely heterogeneous between the
trials, which used a wide variety of different methods to enroll
participants and follow them up. We could not explain the het-
erogeneity in any of the subgroup analyses. Several trials had small
sample sizes, which could have contributed to the heterogeneity
(IntHout 2015).
Evidence about the primary outcome was restricted to people who
did not have symptoms of, or specific risk factors for, STI. The
three RCTs enrolled women taking part in another research study
(Graseck 2010), women attending clinics providing maternal and
child health services (Lippman 2007), andmen contacted through
word of mouth and community outreach (Reagan 2012). The
majority of participants enrolled in the other included trials were
people at high risk of CT or NG because they themselves have
recently been treated or have an infected sexual partner (Andersen
1998; Ostergaard 2003; Cook 2007; Xu 2011; Götz 2013).
Quality of the evidence
In RCTs exploring the outcomes of home-based specimen collec-
tion, where both personnel and participants know which arm of
the trial they are in, adequate allocation concealment is an impor-
tant procedure to minimize selection bias. Reporting of allocation
concealment was adequate in six of 10 included studies. High lev-
els of follow-up are also important; all but one included trial had
more than 20% missing data. The study that included the larger
number of individuals was a cluster RCT that was analysed with-
out taking into account variability within and between clusters.
Only one study reported clear blinding of outcome assessors. No
trial had a high risk of selective reporting bias.
We assessed the quality of evidence provided by the three studies
reporting the primary outcome as moderate, due to study limi-
tations. Trials reporting on positive test prevalence showed mod-
erate-quality evidence that clinic-based specimen collection in-
creased more than home-based specimen collection the number
of participants diagnosed, and we downgraded the quality of evi-
dence due to study limitations (Summary of findings for the main
comparison).
Potential biases in the review process
There is a risk of small-study biases in this review. We performed
an extensive and comprehensive search of electronic databases with
no language restrictions to identify all published and unpublished
trials. Nevertheless, we found only three trials that allowed us to
assess the primary outcome. There were too few trials to draw a
funnel plot. We tried to contact trial authors to obtain additional
information but were not successful. During the review process
three authors carried out the study selection, eligibility assessment
and data extraction to minimize bias in the data collection.
Agreements and disagreements with other
studies or reviews
Odesanmi 2013 reviewed RCTs comparing home-based and
clinic-based specimen collection in women. They found six trials,
all of which we included in this review. In contrast to our review,
the authors considered uptake of testing as an effectiveness out-
come. The authors also found high levels of heterogeneity overall.
In a subgroup analysis of two trials with outcome data derived
from a combination of self-report and medical records they found
reduced heterogeneity and reported an increase in the uptake of
testingwith home-based specimen collection (Jones 2007;Graseck
2010). We identified two additional trials that included women
(Ostergaard 2003; Götz 2013), but one was published after the
end of the search period (Götz 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The review findings are compatible with home-based and clinic-
based specimen collection resulting in similar levels of patients
being treated for CT or NG infection. Home-based specimen
collection appears to encourage more people to be tested, but the
people attending clinics who undergo testing are more likely to
have an STI. The additional yield of tests from those who collect
specimens at home might therefore include people at lower risk
of an STI, whilst people who attend the clinic are those who are
infected.These opposing effects probably explainwhyhome-based
and clinic-based specimen collection resulted in similar rates of
completed testing and treatment in the few trials that documented
this information. The review does not allow any conclusions about
microbiological cure, partner management or re-infection. The
safety of home-based specimen collection compared with clinic-
based specimen collection has not been evaluated.
Implications for research
Test uptake is not a clinically relevant primary outcome for tri-
als because it does not capture the effects of testing strategies on
adequate treatment, follow-up and sexual partner management.
Future RCTs to assess the effectiveness of home-based specimen
collection should be designed to measure biological outcomes of
STI case management, such as proportion of participants with
negative tests for the relevant STI at follow-up.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Andersen 1998
Methods Setting: General practices in Aarhus, Denmark
Study design: Parallel two arms. No specific dates reported.
Sample size estimation a priori: No
Participants Inclusion criteria
• Women
• CT positive
Exclusion criteria
• Not specified
Population
Mean age not reported
96 women with C. trachomatis were randomized, their 133 male sexual partners received
the interventions
Interventions Home-based specimen collection for male sexual partners (n = 65)
Index patients completed a questionnaire about numbers of sexual partners and contacted
their partners to collect first urine sample at home for CT test. Then they returned the
sample to laboratory in a prepaid envelope.
Clinical-based specimen collection for male sexual partners (n = 68)
Not reported if index patients completed questionnaire. Index patients were given an
envelope containing a contact slip and a request to partner to visit his doctor for a urethral
swab sample for CT test. The doctor returned the sample to study laboratory in a prepaid
envelope
Outcomes • Partners contacted (partners receiving a urine sample test kit or contact slip
delivered by index patient)
• Partners tested (review of laboratory records) (44/65) (19/68)
• Partners testing CT positive (review of laboratory records) (12/44) (7/19) and
time until testing (clinical records)
Notes Funding sources: “University of Aarhus, Denmark and Nycomed DAK”
Role of funder: Not reported.
Declarations of interest: None declared.
Not reported if partners testing CT positive were treated. Ethical approval was obtained.
Unclear whether consent was obtained
Number of identifier register: Not found.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote “Ninety six women with C tra-
chomatis infection seen in general prac-
tices in Aarhus County, Denmark, were
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Andersen 1998 (Continued)
randomly divided according to their date
of birth into an intervention group (45 pa-
tients) and a control group (51 patients)”
Allocation concealment (selection bias) Unclear risk Envelopes used for both groups but not
stated if they appeared identical. No details
on allocation concealment given in report
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, the outcomes are likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk No subjective outcomes reported.
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk It is not reported whether the laboratory
personnel or assessors were blinded
Incomplete outcome data (attrition bias)
Short-term outcomes
High risk Intervention group sexual partners tested
were 44/65, control group 19/68. More
than 20% of participants were not tested
and the missing data were not balanced in
the groups
Incomplete outcome data (attrition bias)
Long-term outcomes
Unclear risk Only number of individuals not tested re-
ported; however clearly information was
not available to make a judgement
Selective reporting (reporting bias) Unclear risk Outcomes reported in Methods section
were reported in Results section. Protocol
not available from 3 trial registries
Other bias High risk Participants were sexual partners of CT
positive patients.
Cook 2007
Methods Setting: Community-based medical clinics and its neighbourhoods in Western Pennsyl-
vania.
Study design: Parallel two arms. Enrolment between November 2000 and April 2003
Sample size estimation a priori: Yes.
Participants Inclusion criteria
• Women
• Age 15 to 24 years
• Recent diagnosis with chlamydial, gonococcal or trichomonal infection
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Cook 2007 (Continued)
• Have three of five criteria associated with increased risk of STIs
Exclusion criteria
• Currently pregnant or homeless
Population
Mean age 18.9 years.
420 women were randomized, 211 to home-based strategy and 209 to clinic-based
strategy for CT and NG detection
Interventions Home-based specimen collection (n = 211)
Women in this group completed a questionnaire and received a home-testing kit for CT
and NG at 6, 12 and 18 months with instructions to take a vaginal swab and mail the
sample to the laboratory.
Clinical-based specimen collection (n = 209)
Women assigned to clinical group completed a questionnaire and received a postcard at
6, 12 and 18 months with an invitation to attend to clinic for a routine test for CT and
NG each time
Outcomes • CT and NG tests completed (162/211)(117/209)
• CT and NG infections detected
Notes Funding sources: “US Agency for Healthcare Research and Quality”
Role of funder: Not reported
Declarations of interest: None declared
Women did not receive any reminder or incentive for compliance. They reported rates
of positive tests per 100 woman-years of follow-up. All participants provided informed
consent. The study had ethical approval by participating institutions and clinics
Number of identifier register: ClinicalTrials.gov NCT00177437
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “Women were randomly assigned..
. using a computer-generated blocked ran-
domisation sequence”
Allocation concealment (selection bias) Low risk Group allocation was concealed using
sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding; the outcomes are likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk The study did not address these outcomes.
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Cook 2007 (Continued)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Clinicians and research assistants were
blinded to the participants’ study assign-
ment
Incomplete outcome data (attrition bias)
Short-term outcomes
Unclear risk The number of tested completed at 6, 12
and 18 month was not clearly reported,
missing data were 58% and 56% for inter-
vention and control group respectively
Incomplete outcome data (attrition bias)
Long-term outcomes
Unclear risk Only number of individuals not tested re-
ported; however clearly information was
not available to make a judgement
Selective reporting (reporting bias) Low risk Protocol was available from trial registry.
Primary outcome in protocol same as in
trial
Other bias Unclear risk Both groups had clinical access to usual care
if they were symptomatic
Graseck 2010
Methods Setting: University-based clinic, two abortion clinics, community-based clinics in Mis-
souri, United States
Study design: Parallel two arms. Enrollment ended August 1, 2009.
Sample size estimation a priori: Yes
Participants Inclusion criteria
• Women aged 14 to 45 years
• Participant in Contraceptive CHOICE cohort study
• Using a long-acting reversible method of contraception
• Completed baseline clinical survey in the Contraceptive CHOICE cohort study
Exclusion criteria
• Patients with hysterectomy or tubal sterilization
• Living outside the United States at time of annual STI screening
Population
Mean age 26.1 years home group; and 25.5 years clinic group
548 women were randomized for home-based or clinic-based screening for CT and NG
at 12 months after enrollment
Interventions Home-based specimen collection (n = 268)
A collection kit was mailed to participants in home group: this contained a vaginal swab
and instructions to take the sample and send it to the laboratory by prepaid mail. Baseline
and 12 month follow-up interviews were performed.
Clinical-based specimen collection (n = 280)
Women in clinical groupwere able to test with their regular health care provider or at local
family planning clinics. Baseline and 12 month follow-up interviews were performed
31Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae
infections (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Graseck 2010 (Continued)
Outcomes • CT and NG tests completed (151/268) (92/280)
• CT and NG infections detected (3/151) (5/192)
Notes Funding sources: “Supported inpart by an anonymous foundation,Midcareer Investiga-
tor Award inWomen’s Health Research (K24HD01298), Clinical and Translational Sci-
ence Awards (UL1RR024992), and Award Numbers TL1 RR024995, KL2RR024994,
and K3054628 from theNational Center for Research Resources (NCRR), a component
of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research”
Role of funder: Not reported
Declarations of interest: None declared
All participants with positive test and their sexual partners were treated. Ethical approval
was obtained from Washington University School of Medicine Human Research Pro-
tection Office. All participants provided informed consent
Number of identifier register: ClinicalTrials.gov NCT01184157
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “Women were randomized using
computer-based randomization”
Allocation concealment (selection bias) Low risk Quote “Participants were blinded to ran-
domisation status until time of testing”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, the outcomes are likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk No blinding, assessment of subjective out-
comesmight be influencedby lack of blind-
ing
Blinding of outcome assessment (detection
bias)
Objective outcomes
High risk Investigators were not blinded and lack
of blinding might influence the outcome
measurement
Incomplete outcome data (attrition bias)
Short-term outcomes
Low risk Participants allocated to home-based group
tested were 151/268, control clinic-based
group 163/280 (medical records or speci-
men)
Incomplete outcome data (attrition bias)
Long-term outcomes
Unclear risk Only number of individuals not tested re-
ported; however clearly information was
not available to make a judgement
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Graseck 2010 (Continued)
Selective reporting (reporting bias) Low risk Protocol was available from trial registry.
Primary outcome in protocol same as in
trial
Other bias Low risk No other bias identified.
Götz 2013
Methods Setting: Urban STI clinic in the Netherlands
Study design: Parallel two arms. Enrolment between 15 March and 15 August 2011
Sample size estimation a priori: Yes
Participants Inclusion criteria
• Heterosexual men and women
• CT positive
Exclusion criteria
• Patients with PID, patients with clinically evident signs of infection treated at first
visit, patients notified by a sexual partner
• Pregnant women
• Patients with contra-indications for azithromycin
• Patients under 16 years
• MSM
Population
Mean age not reported.
216 participants with C. trachomatis infection were randomized, 109 to home-based
strategy and 107 to clinic-based strategy for CT retest
Interventions Home-based specimen collection (n = 109)
Patients were entered in a database and completed a questionnaire. Participants were
sent a test kit for retesting at 4 to 5 months after initial treatment. Test kit contained a
sampling tube for urine collection for men or vaginal swab for women, to be sent back
to the laboratory, free of charge. Reminders were sent 2 weeks after no response.
Clinical-based specimen collection (n = 107)
Patients were entered in a database and completed a questionnaire. Participants were
asked to visit the clinic for retesting at 4 to 5 months after initial treatment and received
a test kit with sampling tube for urine collection for men or vaginal swab for women.
Reminders were sent 7 days if no response
Outcomes • CT retest completed (50/109)(25/107)
• CT repeat infections detected (8/50)(5/25)
Notes Funding sources: “ZonMW, Ministry of Health The Netherlands, grant number
12400001 and by RIVM, the Netherlands”
Declarations of interest: None declared.
Role of funder: Not reported.
Not reported if partners’ tests CT positive were treated or if all participants with positive
test were treated. Ethical approval was obtained. Participants provided informed consent
Number of identifier register: Not found.
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Götz 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “Computerized randomisation into.
.. was done using and anonymous list of ID
numbers and sex of participants”
Allocation concealment (selection bias) Unclear risk No details on allocation concealment given
in the report.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, the outcomes are likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk No subjective outcomes reported.
Blinding of outcome assessment (detection
bias)
Objective outcomes
High risk Investigators were not blinded and lack
of blinding might influence the outcome
measurement
Incomplete outcome data (attrition bias)
Short-term outcomes
High risk Home-based groupparticipants testedwere
50/109, clinic-based group 25/107. More
than 20% participants were not tested and
the missing data were not balanced in the
groups
Incomplete outcome data (attrition bias)
Long-term outcomes
Unclear risk Only number of individuals not tested re-
ported ; however clearly information was
not available to make a judgement,
Selective reporting (reporting bias) Unclear risk Protocol was not available from 3 trial reg-
istries. No information available in meth-
ods section to make a judgement,
Other bias High risk Reminders added to management strategy,
also this study evaluated re-testing,
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Jones 2007
Methods Setting: Empilisweni Wellness Center, community-based and public clinics in
Gugulethu, South Africa
Study design: Parallel two arms. Enrollment between September 2003 and August 2004
Sample size estimation a priori: Yes
Participants Inclusion criteria
• Women, aged 14 to 25 years
• At least grade 5 education
Exclusion criteria
• Genital ulcers or gynaecological symptoms in need of immediate care
Population
Mean age 20 years.
626 women were randomized to home-based vs. clinic-based screening for NG, CT and
Trichomonas vaginalis (TV)
Interventions Home-based specimen collection (n = 313)
Participants in home group received a home kit with instructions to take two vaginal
swabs, two questionnaires and educational material, and envelope with pre-paid postage
to return the samples. They had a clinic appointment 6 weeks after enrollment and
reminders were sent on three occasions to contact women who missed this visit.
Clinical-based specimen collection (n = 313)
Participants in the clinic group received an identical kit with educational material and a
clinic appointment card; at the clinic women received two swabs for self-sampling. They
had a clinic appointment 6 weeks after enrollment and reminders were sent on three
occasions to contact women who missed this visit
Outcomes • Test completed (Home 143/313) (Clinic 131/313)
• Feasibility and acceptability of testing
Notes Funding sources: The trial was funded by the Office of Population and Reproduc-
tive Health, Bureau for Global Health, US Agency for International Development and
Parthenon Trust and the William and Flora Hewlett Foundation
Role of funder: Not reported
Declarations of interest: None declared
It is unclear if all participants with positive test and their sexual partners were treated.
Ethical approval was obtained from ethical committees at the University of Cape Town
and the Population Council. All participants provided informed consent
Number of identifier register: Not found
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote “Womenwere randomised... using a
random sequence”, not reported any detail
about the process of sequence generation
Allocation concealment (selection bias) Low risk Group allocation was conceal using sealed
envelopes.
35Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae
infections (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jones 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, the outcomes are likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk No blinding, assessment of subjective out-
comesmight be influencedby lack of blind-
ing
Blinding of outcome assessment (detection
bias)
Objective outcomes
High risk Investigators were not blinded and lack
of blinding might influence the outcome
measurement
Incomplete outcome data (attrition bias)
Short-term outcomes
Unclear risk In home-based group 143/313 participants
were tested and in clinic-based group 131/
313 were tested, the missing data were bal-
anced
Incomplete outcome data (attrition bias)
Long-term outcomes
Unclear risk Only number of individuals not tested re-
ported; however clearly information was
not available to make a judgement
Selective reporting (reporting bias) Unclear risk Protocol was not available from 3 trial reg-
istries. No information available in meth-
ods section to make a judgement
Other bias High risk Reminders added to management strategy.
Lippman 2007
Methods Setting: Low-income clinic population in São Paulo, Brazil
Study design: Parallel two arms. Enrollment between April and November 2004
Sample size estimation a priori: No
Participants Inclusion criteria
• Women, aged 18 to 40 years
• Ability to read and to follow collection and testing instructions
Exclusion criteria
• Not specified
Population
Mean age 27.6 years
818 women were randomized, 410 to home-based strategy and 408 to clinic-based
strategy for CT, TV and NG detection
Interventions Home-based specimen collection (n = 410)
Participants in home group received a kit to take the CT, NG and TV test at home, then
in the following 7 days they had to return the sample to study clinic. They also had a
questionnaire on acceptability.
Clinical-based specimen collection (n = 408)
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Lippman 2007 (Continued)
Participants in clinic group received an identical kit with STI information and an ap-
pointment card for testing at the study clinic. Additionally during the appointment a
pelvic examination was performed and two endocervical samples collected. Afterwards
they answered a questionnaire on acceptability
Outcomes • Test completed (393/410)(394/408)
• Feasibility and acceptability of testing
Notes Funding sources: “this study was funded by the Office of Population and Reproductive
Health, Bureau for Global Health, U.S. Agency for International Development”
Declarations of interest: Not reported
Role of funder: Not reported
Ethical approval was obtained from ethical committees of the Irmandade Santa Casa de
Misericórdia de São Paulo, the Brazilian National Ethics Committee and the Population
Council. All participants provided informed consent
Number of identifier register: Not found
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “identification numbers were ran-
domized before study commencement in
blocks of 16”
Allocation concealment (selection bias) Low risk Group allocation was concealed using
sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, the outcomes are likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk There is not sufficient information to per-
mit judgement
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk It is not reported if the laboratory personnel
or assessors were blinded
Incomplete outcome data (attrition bias)
Short-term outcomes
Low risk Participants tested in home-based group
were 393/410 and 394/408 in clinic-based
group
Incomplete outcome data (attrition bias)
Long-term outcomes
Unclear risk Only one long-term outcome was eval-
uated, number of individuals not tested;
however clearly information was not avail-
able to make a judgement
37Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae
infections (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lippman 2007 (Continued)
Selective reporting (reporting bias) Unclear risk Protocol was not available from 3 trial reg-
istries. No information available in meth-
ods section to make a judgement
Other bias High risk Reminders added to management strategy
Ostergaard 1998
Methods Setting: High schools in Aarhus, Denmark
Study design: Cluster randomized trial, parallel two arms. Enrollment between January
1997 and April 1997
Sample size estimation a priori: No
Participants Inclusion criteria
• Male and female students who returned the questionnaire and were sexually
experienced
Exclusion criteria
• Not specified
Population
Mean age females 18 years, males 18.2 years.
8909 students were randomized, 4336 to home-based strategy (2603 women and 1733
men) and 4573 to clinic-based strategy (2884 women and 1689 men) for CT detection.
To deal with unit analysis issues about cluster-randomized studies we used an ICC 0,
00119, average cluster size of 524; hence the effective sample size for home group was
2673 and 2819 for clinic group
Interventions Home-based specimen collection (n = 2673)
In the home group the students completed a questionnaire and received information
regarding CT infection; female students were asked to collect two urine samples and one
vaginal flush sample, males were asked to collect one first void urine sample and mail
from home to the laboratory.
Clinical-based specimen collection (n = 2819)
In the clinic group the students completed a questionnaire and received information
regarding CT infection; they were offered a free test from their doctor or at the local
clinic
Outcomes • Number of students tested (799/2673)(41/2819)
• Number of students infected (33/799)(4/41)
Notes Funding sources: “The study was funded by the Danish National Board of Health,
Løvens Kemiske Fabriks Research Foundation, Nycomed DAK, Pfizer, and Chairman
Jacob Madsen and Hustru Olga Madsen’s foundation”
Role of funder: Not reported
Declarations of interest: None declared
It is unclear if all participants with positive test and their sexual partners were treated.
Ethical approval was obtained from ethics committee and the Danish Data Protection
Agency. Unclear whether consent was obtained
Number of identifier register: Not found
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Ostergaard 1998 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote “We randomised all 17 high
schools”: details about the process of se-
quence generation for cluster-randomiza-
tion not reported
Allocation concealment (selection bias) Unclear risk No details on allocation concealment given
in the report.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, the outcomes are likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk No subjective outcomes reported.
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk It is not reported if the laboratory personnel
or assessors were blinded
Incomplete outcome data (attrition bias)
Short-term outcomes
High risk After we used the effective sample size
for this cluster-randomized study, the at-
trition rate was 799/2673 for home-based
group; and for clinic-based group it was 41/
2819. More than 20% participants were
not tested and the missing data were not
balanced in the groups
Incomplete outcome data (attrition bias)
Long-term outcomes
Unclear risk Only number of individuals not tested re-
ported; however clearly information was
not available to make a judgement
Selective reporting (reporting bias) Unclear risk Protocol was not available from 3 trial reg-
istries. No information available in meth-
ods section to make a judgement
Other bias Unclear risk No other bias identified.
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Ostergaard 2003
Methods Setting: General practices in four counties in Denmark
Study design: Parallel two arms. Enrollment between February 1999 and March 2000
Sample size estimation a priori: No
Participants Inclusion criteria
• Patients with CT positive swab in the routine laboratory
• Completed questionnaire
Exclusion criteria
• Not specified
Population
Mean age index women 23 years, index men 25 years.
1826 patients with C. trachomatis-positive swab test were randomized, 734 sexual part-
ners were contacted and they received the intervention: 398 received the home-based
strategy (342 women and 56 men); and 336 received the clinic-based strategy (289
women and 47 men) for CT detection
Interventions Home-based specimen collection for sexual partners (n = 398)
Index patients gave or mailed the collection kit to their partners; in the home group the
partners mailed the samples to the laboratory in post-paid envelopes.
Clinical-based specimen collection for sexual partners (n = 336)
In the office group partners needed to go to heath care provider to obtain a sample, using
the provided specimen collection kit
Outcomes • Number of sexual partners tested (233/398)(97/336)
• Number of sexual partners infected (91/233)(50/97)
Notes Funding sources: “The study was supported by grants from the Danish National Board
of Health, Danish Medical Research Council, Danish Centre for Evaluation and Health
TechnologyAssessment (DACEHTA), AageBang’s Fund,Helga og PeterKornings Fond,
and Pfizer Denmark A/S”
Role of funder: Not reported
Declarations of interest: None declared
It is unclear if all participants with positive test and their sexual partners were treated.
Ethical approval was obtained from theDanish ethics committee system. Implied consent
Number of identifier register: Not found
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote “We randomised the index pa-
tients”, details about the process of se-
quence generation not reported
Allocation concealment (selection bias) Low risk Allocation was done by central randomiza-
tion
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Ostergaard 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, the outcomes are likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk No subjective outcomes reported
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk It is not reported if the laboratory personnel
or assessors were blinded
Incomplete outcome data (attrition bias)
Short-term outcomes
High risk In home-based group 233/398 participants
were tested and in clinic-based group 97/
336 were tested. More than 20% partici-
pants were not tested and the missing data
were not balanced in the groups
Incomplete outcome data (attrition bias)
Long-term outcomes
Unclear risk Only number of individuals not tested re-
ported; however clearly information was
not available to make a judgement
Selective reporting (reporting bias) Unclear risk Protocol was not available from 3 trial reg-
istries. No information available in meth-
ods section to make a judgement
Other bias High risk Participants were sexual partners of CT
positive patients
Reagan 2012
Methods Setting: Low-income area health clinics and local colleges, word of mouth self referral,
and a WU school of Medicine outreach group in St. Louis Missouri, United States
Study design: Parallel two arms. Enrollment between June 2011 and September 2011
Sample size estimation a priori: Yes
Participants Inclusion criteria
• Men aged 18 to 45 years
• Residing in St. Louis City or County
• English-speaking
Exclusion criteria
• Not specified
Population
Mean age 31.2 home group. 30.3 clinic group.
200 men were randomized, 100 to home-based strategy and 100 to clinic-based strategy
for CT and NG detection
41Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae
infections (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Reagan 2012 (Continued)
Interventions Home-based specimen collection (n = 100)
Participants received a screening kit at their address to collect a urine sample at home.
Then they returned the urine sample to laboratory through prepaid mailer. They com-
pleted a baseline and follow-up questionnaire
Clinical-based specimen collection (n = 100)
Participants in clinic group received a screening kit on arrival at the research clinic, they
collected the urine sample and returned it to the staff. They completed a baseline and
follow-up questionnaire
Outcomes • Number of men who complete testing (72/100)(48/100)
• Number of CT and NG infections detected (4/72)(3/48)
Notes Funding sources: Anonymous Foundation, National Institutes of Health (NIH) and
grant from the Doris Duke Charitable Foundation
Role of funder: Not reported
Declarations of interest: None
It is unclear if all participants with positive test and their sexual partners were treated.
Ethical approval was obtained from ethical committees of Washington University in St.
Louis Human Research Protection Office. All participants provided informed consent
Number of identifier register: ClinicalTrials.gov NCT01654991
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “Using a computer-generated 1:1
randomization scheme... by random gen-
erator function”
Allocation concealment (selection bias) Unclear risk No details on allocation concealment given
in the report
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, the outcomes are likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk No subjective outcomes reported
Blinding of outcome assessment (detection
bias)
Objective outcomes
High risk Investigators were not blinded and lack
of blinding might influence the outcome
measurement
Incomplete outcome data (attrition bias)
Short-term outcomes
High risk In home-based group 72/100 participants
were tested and in clinic-based group 48/
100 were tested. More than 20% partici-
pants were not tested and the missing data
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Reagan 2012 (Continued)
were not balanced in the group
Incomplete outcome data (attrition bias)
Long-term outcomes
Unclear risk Only number of individuals not tested re-
ported; however clearly information was
not available to make a judgement
Selective reporting (reporting bias) Low risk Protocol was available from trial registry.
Primary outcome in protocol same as in
trial
Other bias High risk Use of an economic incentive for partici-
pants
Xu 2011
Methods Setting: STI clinics and family planning clinics in New Orleans, Louisiana, St Louis,
Missouri, and Jackson, Mississippi, United States
Study design: Parallel two arms. Enrollment between 2005 and 2007
Sample size estimation a priori: Yes
Participants Inclusion criteria
• Women 16 years and older
• CT positive
Exclusion criteria
• Pregnant or women trying to conceive
• Women who are planning to move in the following 3 months
• Currently living outside the study areas
• Inability to understand spoken English adequately
• Self-reported HIV infection, other serious illnesses or disability
• Self-reported allergy to macrolide antibiotics such as azithromycin
• Referrals from providers or clinics other than the STD or family planning clinics,
unless women are re-tested at the STD clinics and test positive for chlamydia
Population
Mean age 22 years.
1292 women with C. trachomatis infection were randomized to rescreening, 639 to
home-based strategy and 653 to clinic-based strategy
Interventions Home-based specimen collection (n = 639)
Participants in home group were mailed a vaginal swab kit for self collection at home
and they returned the sample via mail
Clinical-based specimen collection (n = 653)
Participants in clinic group were given an appointment to return to clinics for rescreening
for CT infection
Outcomes • Rescreening 3 months after treatment (189/639)(120/653)
• Reinfection (29/189)(27/120)
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Xu 2011 (Continued)
Notes Funding sources: “Funded by Centers for Disease Control and Prevention”
Role of funder: Not reported
Declarations of interest: None declared
It is unclear if all participants with positive test and their sexual partners were treated.
Ethical approval was obtained from ethical committees of Louisiana State University
Health Sciences Center, Washington University, University of Mississippi State Depart-
ment of Health, and the CDC. All participants provided informed consent
Number of identifier register: ClinicalTrials.gov NCT00132457
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “Women were randomly assigned...
according to a random number generator..
. with a block size of 12”
Allocation concealment (selection bias) Low risk Group allocation was concealed using
sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, the outcomes are likely to be
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk No subjective outcomes reported
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk It is not reported if the laboratory personnel
or assessors were blinded
Incomplete outcome data (attrition bias)
Short-term outcomes
High risk In home-based group 189/639 participants
were tested and in clinic-based group 120/
653 were tested. More than 20% partici-
pants were not tested and the missing data
were not balanced in the group
Incomplete outcome data (attrition bias)
Long-term outcomes
Unclear risk Only number of individuals not tested re-
ported; however clearly information was
not available to make a judgement
Selective reporting (reporting bias) Low risk Protocol was available from trial registry.
Primary outcome in protocol same as in
trial
Other bias High risk Reminders added to management strategy,
also this study evaluated re-testing
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CT = Chlamydia trachomatis
NG = Neisseria gonorrhoeae
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andersen 2002 No comparison, usual care, only symptomatic participants were evaluated
Andersen 2011 No comparison, usual care, only symptomatic participants were evaluated. Follow-up 9 years after Andersen
2002
Buhrer-Skinner 2011 Not an RCT
Emmerton 2011 Not an RCT
Falk 2014 Not an RCT
Gray 1998 Not an RCT
Klovstad 2013 No comparison, usual care, only symptomatic participants were evaluated
Ostergaard 1999 Duplicate in Dutch language from Ostergaard 1998
Ostergaard 2000 Reports on 1 year follow-up for Ostergaard 1998, new data were added to the included study
Scholes 2007 No comparison, usual care, only symptomatic participants were evaluated
Sparks 2004 Not an RCT
Van Valkengoed 2002 Not an RCT
RCT: randomized controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Apoola 2009
Methods Setting: Genito-Urinary clinic in Derbyshire, UK
Study design: RCT, parallel two arms. Enrollment between February 28 2006 and March 31 2007
Funding sources: None
Declarations of interest: None declared
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Apoola 2009 (Continued)
Participants Inclusion criteria
• Women
• CT positive
Exclusion criteria
• Patients whose sexual contacts are not in Derbyshire or are untraceable
• Sexual contacts under the age of 16
Population
200 women with C. trachomatis infection were randomized to partner notification, 100 to swab testing arm and 100
to urine testing arm
Interventions Swab testing arm (n = 100)
Conventional partner notification using urethral swab test at clinic
Urine testing arm (n = 100)
Index patient gave to male sexual partners contact slip and urine sampling kit to collect the sample at home and then
return to clinic for diagnosis and management
Outcomes Number of partners treated per index case
Notes We wrote to contact author for further information about outcome data of exact number of sexual partners, but we
did not obtain any information
Characteristics of ongoing studies [ordered by study ID]
De Barbeyrac 2013
Trial name or title Chlamy-web
Methods RCT
Participants Young people 18 to 24 years old recruitment on Internet information web site
Interventions Free home-based self-sampling test vs traditional information system at screening center
Outcomes Self-sampling was proposed to 5531 people, 1616 were tested, global prevalence 6.8%
Starting date Not reported
Contact information Bertille.de-Barbeyrac@u-bordeaux.fr
Notes This study is still ongoing, there are no data on traditional screening. The authors did not provide more
information
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Smith 2014
Trial name or title REACT: a randomized controlled trial assessing the effectiveness of home-collection to increase chlamydia
retesting and detect repeat positive tests
Methods Non-blinded, randomized controlled trial
Participants Heterosexual men, MSM or women who have a diagnosis of chlamydia infection
Interventions SMS reminder and home-based, self-collected samples or an SMS reminder and clinic testing
Outcomes Proportion of patients who retest between 1 to 4 months after a chlamydia diagnosis, repeat positive test rate,
reinfection rate, acceptability of home testing with SMS reminders and cost effectiveness of home testing
Starting date Not reported
Contact information ksmith@kirby.unsw.edu.au
Notes Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12611000968976
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D A T A A N D A N A L Y S E S
Comparison 1. Home-based vs clinic-based specimen collection for CT and NG
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Index Case Management 3 1566 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.60, 1.29]
2 Proportion of individuals tested 10 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Proportion of individual tested
grouped by sex
9 Odds Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Female 7 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Male 4 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Proportion of individual tested
grouped by risk
10 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 High Risk 5 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Low Risk 5 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Proportion of individual
tested grouped by method of
returning specimens
10 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5.1 Mail 9 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Personally 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Proportion of individual tested
grouped by use of reminders
7 Risk Difference (M-H, Random, 95% CI) Totals not selected
6.1 No reminders 2 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Reminders 5 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Positive test prevalence 9 3041 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.61, 0.86]
48Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae
infections (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Home-based vs clinic-based specimen collection for CT and NG, Outcome 1
Index Case Management.
Review: Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections
Comparison: 1 Home-based vs clinic-based specimen collection for CT and NG
Outcome: 1 Index Case Management
Study or subgroup Home Clinic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Graseck 2010 3/268 5/280 9.6 % 0.63 [ 0.15, 2.60 ]
Lippman 2007 38/410 43/408 84.5 % 0.88 [ 0.58, 1.33 ]
Reagan 2012 4/100 3/100 5.9 % 1.33 [ 0.31, 5.81 ]
Total (95% CI) 778 788 100.0 % 0.88 [ 0.60, 1.29 ]
Total events: 45 (Home), 51 (Clinic)
Heterogeneity: Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Clinic Favours Home
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Analysis 1.2. Comparison 1 Home-based vs clinic-based specimen collection for CT and NG, Outcome 2
Proportion of individuals tested.
Review: Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections
Comparison: 1 Home-based vs clinic-based specimen collection for CT and NG
Outcome: 2 Proportion of individuals tested
Study or subgroup Home Clinic Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Andersen 1998 44/65 19/68 2.42 [ 1.60, 3.68 ]
Cook 2007 162/211 117/209 1.37 [ 1.19, 1.58 ]
Graseck 2010 151/268 92/280 1.71 [ 1.41, 2.09 ]
Go¨tz 2013 50/109 25/107 1.96 [ 1.32, 2.93 ]
Jones 2007 143/313 131/313 1.09 [ 0.91, 1.30 ]
Lippman 2007 393/410 394/408 0.99 [ 0.97, 1.02 ]
Ostergaard 1998 799/2673 41/2819 20.55 [ 15.08, 28.00 ]
Ostergaard 2003 233/398 97/336 2.03 [ 1.68, 2.45 ]
Reagan 2012 72/100 48/100 1.50 [ 1.18, 1.90 ]
Xu 2011 189/639 120/653 1.61 [ 1.32, 1.97 ]
0.01 0.1 1 10 100
Favours Clinic Favours Home
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Analysis 1.3. Comparison 1 Home-based vs clinic-based specimen collection for CT and NG, Outcome 3
Proportion of individual tested grouped by sex.
Review: Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections
Comparison: 1 Home-based vs clinic-based specimen collection for CT and NG
Outcome: 3 Proportion of individual tested grouped by sex
Study or subgroup Home Clinic Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Female
Cook 2007 162/211 117/209 2.60 [ 1.71, 3.96 ]
Graseck 2010 151/268 92/280 2.64 [ 1.86, 3.73 ]
Jones 2007 143/313 131/313 1.17 [ 0.85, 1.60 ]
Lippman 2007 393/410 394/408 0.82 [ 0.40, 1.69 ]
Ostergaard 1998 534/1605 39/1778 22.23 [ 15.92, 31.05 ]
Ostergaard 2003 38/56 9/47 8.91 [ 3.56, 22.32 ]
Xu 2011 189/639 120/653 1.87 [ 1.44, 2.42 ]
2 Male
Andersen 1998 44/65 19/68 5.40 [ 2.57, 11.35 ]
Ostergaard 1998 265/1068 2/1041 171.44 [ 42.52, 691.19 ]
Ostergaard 2003 195/342 88/289 3.03 [ 2.18, 4.21 ]
Reagan 2012 72/100 48/100 2.79 [ 1.55, 5.01 ]
0.01 0.1 1 10 100
Favours Clinic Favours Home
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Analysis 1.4. Comparison 1 Home-based vs clinic-based specimen collection for CT and NG, Outcome 4
Proportion of individual tested grouped by risk.
Review: Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections
Comparison: 1 Home-based vs clinic-based specimen collection for CT and NG
Outcome: 4 Proportion of individual tested grouped by risk
Study or subgroup Favours Clinic Clinic Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 High Risk
Andersen 1998 44/65 19/68 2.42 [ 1.60, 3.68 ]
Cook 2007 162/211 117/209 1.37 [ 1.19, 1.58 ]
Go¨tz 2013 50/109 25/107 1.96 [ 1.32, 2.93 ]
Ostergaard 2003 233/398 97/336 2.03 [ 1.68, 2.45 ]
Xu 2011 189/639 120/653 1.61 [ 1.32, 1.97 ]
2 Low Risk
Graseck 2010 151/268 92/280 1.71 [ 1.41, 2.09 ]
Jones 2007 143/313 131/313 1.09 [ 0.91, 1.30 ]
Lippman 2007 393/410 394/408 0.99 [ 0.97, 1.02 ]
Ostergaard 1998 799/2673 41/2819 20.55 [ 15.08, 28.00 ]
Reagan 2012 72/100 48/100 1.50 [ 1.18, 1.90 ]
0.01 0.1 1 10 100
Favours Clinic Favours Home
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Analysis 1.5. Comparison 1 Home-based vs clinic-based specimen collection for CT and NG, Outcome 5
Proportion of individual tested grouped by method of returning specimens.
Review: Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections
Comparison: 1 Home-based vs clinic-based specimen collection for CT and NG
Outcome: 5 Proportion of individual tested grouped by method of returning specimens
Study or subgroup Favours Clinic Clinic Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mail
Andersen 1998 44/65 19/68 2.42 [ 1.60, 3.68 ]
Cook 2007 162/211 117/209 1.37 [ 1.19, 1.58 ]
Graseck 2010 151/268 92/280 1.71 [ 1.41, 2.09 ]
Go¨tz 2013 50/109 25/107 1.96 [ 1.32, 2.93 ]
Jones 2007 143/313 131/313 1.09 [ 0.91, 1.30 ]
Ostergaard 1998 799/2673 41/2819 20.55 [ 15.08, 28.00 ]
Ostergaard 2003 233/398 97/336 2.03 [ 1.68, 2.45 ]
Reagan 2012 72/100 48/100 1.50 [ 1.18, 1.90 ]
Xu 2011 189/639 120/653 1.61 [ 1.32, 1.97 ]
2 Personally
Lippman 2007 393/410 394/408 0.99 [ 0.97, 1.02 ]
0.5 0.7 1 1.5 2
Favours Clinic Favours Home
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Analysis 1.6. Comparison 1 Home-based vs clinic-based specimen collection for CT and NG, Outcome 6
Proportion of individual tested grouped by use of reminders.
Review: Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections
Comparison: 1 Home-based vs clinic-based specimen collection for CT and NG
Outcome: 6 Proportion of individual tested grouped by use of reminders
Study or subgroup Home Clinic
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 No reminders
Graseck 2010 151/268 92/280 0.23 [ 0.15, 0.32 ]
Reagan 2012 72/100 48/100 0.24 [ 0.11, 0.37 ]
2 Reminders
Cook 2007 162/211 117/209 0.21 [ 0.12, 0.30 ]
Go¨tz 2013 50/109 25/107 0.23 [ 0.10, 0.35 ]
Jones 2007 143/313 131/313 0.04 [ -0.04, 0.12 ]
Lippman 2007 393/410 394/408 -0.01 [ -0.03, 0.02 ]
Xu 2011 189/639 120/653 0.11 [ 0.07, 0.16 ]
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Analysis 1.7. Comparison 1 Home-based vs clinic-based specimen collection for CT and NG, Outcome 7
Positive test prevalence.
Review: Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections
Comparison: 1 Home-based vs clinic-based specimen collection for CT and NG
Outcome: 7 Positive test prevalence
Study or subgroup Home Clinic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Andersen 1998 12/44 7/19 4.5 % 0.74 [ 0.35, 1.58 ]
Graseck 2010 3/151 5/92 2.9 % 0.37 [ 0.09, 1.49 ]
Go¨tz 2013 8/50 5/25 3.1 % 0.80 [ 0.29, 2.19 ]
Jones 2007 21/143 35/131 16.8 % 0.55 [ 0.34, 0.89 ]
Lippman 2007 39/393 43/394 19.8 % 0.91 [ 0.60, 1.37 ]
Ostergaard 1998 33/799 4/41 3.5 % 0.42 [ 0.16, 1.14 ]
Ostergaard 2003 91/233 50/97 32.5 % 0.76 [ 0.59, 0.97 ]
Reagan 2012 4/72 3/48 1.7 % 0.89 [ 0.21, 3.80 ]
Xu 2011 29/189 27/120 15.2 % 0.68 [ 0.43, 1.09 ]
Total (95% CI) 2074 967 100.0 % 0.72 [ 0.61, 0.86 ]
Total events: 240 (Home), 179 (Clinic)
Heterogeneity: Chi2 = 4.76, df = 8 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.71 (P = 0.00020)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Strategy components for CT and NG detection
Component Home-based strategy Clinic-based strategy
1. Place of specimen collection Home-based Clinic-based
2. Process for specimen collection Self-collected Self-collected or physician collected
3. Specimen collection device Could differ Could differ
4. Specimen transport conditions Possible mailing delays, ambient tempera-
tures
Should have fewer delays, may have cold
chain
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Table 1. Strategy components for CT and NG detection (Continued)
5. Specimen delivery Patient mails or delivers to laboratory or
clinic
No involvement for patient
6. Specimen processing Same Same
7. Accuracy of the diagnostic test Same Same
8. Process for notifying provider of results Same Same
9. Process for notifying patient of results Could differ Could differ
10. Treatment Same Same
11. Partner management and patient fol-
low-up
Same Same
A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE and CENTRAL (Ovid platform)
1 exp Chlamydia trachomatis/
2 (chlam?dia adj5 trachomatis).tw.
3 (chlamydozoon adj5 trachomatis)
4 (rickettsia adj5 trachoma$).tw.
5 exp Chlamydia Infections/
6 (chlamydi?sis).tw.
7 (chlamydia$ adj5 infection$).tw.
8 exp Urethritis/
9 (chlamydia$ adj5 urethritis).tw.
10 (urogenital adj5 chlamydia$).tw.
11 exp Neisseria gonorrhoeae/
12 (neisseria adj5 gonorrhoeae).tw.
13 (gonococcus).tw.
14 (diplococcus adj5 neisser).tw.
15 exp Gonorrhea/
16 (gonococc$ adj5 infection$).tw.
17 (gonococcosis).tw.
18 (gonorrhoea).tw.
19 (gonorrh?eae).tw.
20 (gonorrhea$).tw.
21 (gonococ$ adj5 urethritis).tw.
22 (gonorrh$ adj5 urethritis).tw
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23 (specific adj5 urethritis).tw.
24 or/1-23
25 (home adj5 screen$).tw.
26 (home adj5 collect$).tw.
27 (home adj5 sampl$).tw.
28 (home adj5 specimen$).tw.
29 (home adj5 test$).tw.
30 (home adj5 kit$).tw.
31 (clinic$ adj5 screen$).tw.
32 (clinic$ adj5 collect$).tw.
33 (clinic$ adj5 sampl$).tw.
34 (clinic$ adj5 specimen$).tw.
35 (clinic$ adj5 test$).tw.
36 (physician adj5 collect$).tw.
37 (medic$ adj5 collect$).tw.
38 exp Self-Examination/
39 (self adj5 collect$).tw.
40 (self adj5 exam$).tw.
41 (self adj5 sampl$).tw.
42 (auto adj5 collect$).tw.
43 (self adj5 test$).tw.
44 (self adj5 specimen$).tw.
45 (specimen$ adj5 collect$).tw.
46 (mail$ adj5 collect$).tw.
47 (mail$ adj5 return$).tw.
48 (screen$ adj5 test$).tw.
49 or/25-48
50 randomized controlled trial.pt.
51 controlled clinical trial.pt.
52 randomized.ab.
53 placebo.ab.
54 clinical trials as topic.sh.
55 randomly.ab.
56 trial.ti.
57 or/50-56
58 exp animals/ not humans.sh.
59 57 not 58
60 24 and 49 and 59
Note: the CENTRAL search strategy does not include the lines #50 - #59.
EMBASE (embase.com platform)
1 ’Chlamydia trachomatis’/exp
2 (chlamidia NEAR/5 trachomatis):ab,ti
3 (chlamydia NEAR/5 trachomatis):ab,ti
4 (chlamydozoon NEAR/5 trachomatis):ab,ti
5 (rickettsia NEAR/5 trachoma*):ab,ti
6 ’chlamydiasis’/exp
7 (chlamydiasis):ab,ti
8 (chlamydiosis):ab,ti
9 (chlamydia* NEAR/5 infection*):ab,ti
10 ’chlamydial urethritis’/exp
11 (chlamydia* NEAR/5 urethritis):ab,ti
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12 (urogenital NEAR/5 chlamydia*):ab,ti
13 ’Neisseria gonorrhoeae’/exp
14 (neisseria NEAR/5 gonorrhoeae):ab,ti
15 (gonococcus):ab,ti
16 (diplococcus NEAR/5 neisser):ab,ti
17 ’gonorrhea’/exp
18 (gonococc* NEAR/5 infection*):ab,ti
19 (gonococcosis):ab,ti
20 (gonorrhoea):ab,ti
21 (gonorrhaeae):ab,ti
22 (gonorrhoeae):ab,ti
23 (gonorrhea*):ab,ti
24 ’gonococcal urethritis’/exp
25 (gonococ* NEAR/5 urethritis):ab,ti
26 (gonorrh* NEAR/5 urethritis):ab,ti
27 (specific NEAR/5 urethritis):ab,ti
28 or/1-27
29 (home NEAR/5 screen*):ab,ti
30 (home NEAR/5 collect*):ab,ti
31 (home NEAR/5 sampl*):ab,ti
32 (home NEAR/5 specimen*):ab,ti
33 (home NEAR/5 test*):ab,ti
34 (home NEAR/5 kit*):ab,ti
35 (clinic* NEAR/5 screen*):ab,ti
36 (clinic* NEAR/5 collect*):ab,ti
37 (clinic* NEAR/5 sampl*):ab,ti
38 (clinic* NEAR/5 specimen*):ab,ti
39 (clinic* NEAR/5 test*):ab,ti
40 (physician NEAR/5 collect*):ab,ti
41 (medic* NEAR/5 collect*):ab,ti
42 ’self examination’/exp
43 (self NEAR/5 collect*):ab,ti
44 (self NEAR/5 exam*):ab,ti
45 (self NEAR/5 sampl*):ab,ti
46 (auto NEAR/5 collect*):ab,ti
47 (self NEAR/5 test*):ab,ti
48 (self NEAR/5 specimen*):ab,ti
49 (specimen* NEAR/5 collect*):ab,ti
50 (mail* NEAR/5 collect*):ab,ti
51 (mail* NEAR/5 return*):ab,ti
52 ’screening test’/exp
53 (screen* NEAR/5 test*):ab,ti
54 or/29-53
55 ’clinical trial’/exp
56 ’randomized controlled trial’/exp
57 ’randomization’/exp
58 ’single blind procedure’/exp
59 ’double blind procedure’/exp
60 ’crossover procedure’/exp
61 ’placebo’/exp
62 (randomised NEAR/2 controlled NEAR/2 trial*) :ab,ti
63 (randomized NEAR/2 controlled NEAR/2 trial*) :ab,ti
64 rct :ab,ti
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65 (random NEAR/2 allocation) :ab,ti
66 (randomly NEAR/2 allocated) :ab,ti
67 (allocated NEAR/2 randomly) :ab,ti
68 (allocated NEAR/2 random) :ab,ti
69 (single NEAR/2 blind*) :ab,ti
70 (double NEAR/2 blind*) :ab,ti
71 (triple NEAR/2 blind *) :ab,ti
72 (placebo*) :ab,ti
73 ’prospective study’/exp
74 or/55-73
75 ’case study’/exp
76 case report :ab,ti
77 ’abstract report’/exp
78 ’letter’/exp
79 or/75-78
80 74 not 79
81 ’animals’/exp
82 ’invertebrate’/exp
83 ’animal experiment’/exp
84 ’animal model’/exp
85 ’animal tissue’/exp
86 ’animal cell’/exp
87 ’nonhuman’/exp
88 or/81-87
88 ’human’/exp
89 ’normal human’/exp
90 ’human cell’/exp
91 or/88-90
92 88 and 91
93 88 not 92
94 80 not 93
95 28 and 54 and 94
Sexually Transmitted Infections Cochrane Review Group’s Specialized Register
Using the terms “Chlamydia trachomatis” OR “ Neisseria gonorrhoeae” AND “screen” in title, abstract and keywords.
C O N T R I B U T I O N S O F A U T H O R S
1. Draft the protocol: LF, HG, EA, CR, NL
2. Study selection: PV, LF HG, JA
3. Extract data from studies: PV, LF, EA
4. Enter data into RevMan: LF
5. Carry out the analysis: CR, LF, EA
6. Interpret the analysis: LF, HG, EA, CR, NL
7. Draft the final review: LF, HG, EA, CR, NL
8. Disagreement resolution: HG
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9. Update the review: LF, HG, EA, CR
D E C L A R A T I O N S O F I N T E R E S T
None known
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Anne Anderson Award 2013, USA.
This review was supported by the Anne Anderson Award, its goal is to recognize and stimulate individuals contributing to the
enhancement of women’s visibility and participation in the Cochrane leadership, 2013 Recipient was Professor Cindy Farquhar and
Designee Luisa Fajardo Bernal.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We changed the name of the primary outcome to “index case management”, rather than “complete case management”.
We failed to implement some methods planned in our protocol, including analysis of measures of effect for continuous outcomes, and
the unit of analysis issue for studies with multiple treatment groups, because of a lack of pertinent data. These methods may be relevant
for future updates. We included one subgroup analysis that we did not state in the protocol: for the secondary outcome “proportion
of individuals tested”, we examined the findings according to the use of reminders. For the subgroup analyses to assess heterogeneity
in random-effects models, we used meta-regression to estimate the ratio of risk ratios (RRR, with 95% CI).
The ’Summary of findings’ table was restricted to four outcomes: index case management, proportion of individuals tested, positive test
prevalence, and adverse effects of testing. We added the secondary outcome “proportion of individuals tested” that was not prespecified
in the protocol. We did not include the outcomes of infection cured, barriers to testing and costs because we did not find RCTs that
evaluated these outcomes.
Patrick Vigil has been added as an author since the protocol was published.
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